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A disproportionate amount of dollars are spent to provide specialized early 
intervention services to a number of preterm children in the first months and years of 
life, despite mounting evidence that these services benefit only a small percentage of 
preterm babies who are truly at high risk for neurodevelopmental disability and delay.  
Unfortunately, there is no “gold standard” test or procedure for identification of at-
risk preterm infants, and it is extremely difficult for the neonatal care provider to 
determine which preterm babies will gain the most benefit from early intervention 
services.  The Premie-Neuro is a new standardized clinical neurological assessment 
tool that may aid the clinician in identifying at-risk preterm infants, but its 
psychometric properties have not been established.  In this study, we set out to answer 
three primary questions about the Premie-Neuro.  Does the Premie-Neuro have 
adequate reliability and construct validity for clinical use?  Is Premie-Neuro 
performance predictive of neurodevelopmental disability and delay at term and post-
term ages?  Are there modifications of the Premie-Neuro that may enhance its 
reliability, validity, predictive value, and clinical use? 
In Chapter 2, we evaluated the reliability and construct validity of the Premie-
Neuro by using the tool to test 34 preterm infants in the neonatal intensive care unit 
(NICU).  The Premie-Neuro was administered to each infant twice by the same 
examiner, no more than 72 hours apart, then continued to be administered by the 
same examiner weekly through 37 weeks post-menstrual age (PMA) or discharge 
from the NICU.  One Premie-Neuro assessment per infant was observed and scored 
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by a second examiner.  At NICU discharge, infants’ medical charts were reviewed to 
determine risk for poor neurological outcomes.  Our results showed that the Premie-
Neuro raw scores had fair to moderate test-retest and interrater reliability and 
discriminated between groups of infants known to differ in terms of risk.  However, 
the Premie-Neuro classifications (abnormal, questionable, or normal) based on the 
authors’ recommended raw score cut-points were not reliable or valid.  This study 
showed that the Premie-Neuro raw scores had acceptable reliability and validity for 
use by the clinician to identify at-risk preterm infants, but that the Premie-Neuro 
classifications should be interpreted cautiously. 
Predictive validity of standardized assessment tools is of great interest to the 
neonatal care provider.  A predictive tool allows the clinician to make a long-term 
prognosis for a preterm infant’s development and function, and can provide guidance 
for discharge planning and follow-up care.  In Chapter 3, we examined whether 
Premie-Neuro performance in the NICU was predictive of outcomes at term and three 
months adjusted age.  As in Chapter 2, we tested preterm babies using the Premie-
Neuro each week through 37 weeks PMA or NICU discharge.  Infants were then 
tested at term adjusted age (38-42 weeks PMA) using the NeoNeuro and at 3 months 
adjusted age using the Alberta Infant Motor Scale (AIMS) and Infanib.  We found 
that, while early Premie-Neuro scores had some predictive value, Premie-Neuro raw 
scores obtained just before NICU discharge were significantly predictive of 
performance on all assessments administered at term and three months adjusted age.  
However, the Premie-Neuro classifications were generally not predictive of term and 
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three-month outcomes.  We concluded that the clinician may use discharge Premie-
Neuro raw scores to predict term and three-month outcomes for preterm infants.  
Again, we recommended that the clinician use caution when interpreting Premie-
Neuro classifications based on the authors’ recommended raw score cut-points. 
In Chapters 2 and 3, we found the Premie-Neuro raw scores—but not 
classifications—to be psychometrically sound.  Thus, in Chapter 4, we set out to 
determine whether modifying the raw score cut-points for making Premie-Neuro 
classifications may improve the tool’s reliability and validity.  In Chapter 4, we 
retrospectively analyzed predictive validity data presented in Chapter 3 to determine 
whether infants with normal versus abnormal outcomes at term and/or three-months 
adjusted age performed significantly differently on the Premie-Neuro in the NICU.  
We found that, after 34 weeks PMA, mean Premie-Neuro scores for infants with 
abnormal follow-up were less than 90, and that infants with discharge Premie-Neuro 
raw scores less than 90 performed significantly worse on term and 3-month follow-up 
assessments than infants with scores 100 or greater.  Using a discharge Premie-Neuro 
raw score cut-point of <90 (rather than the authors’ recommended cut-point of <100) 
to classify a Premie-Neuro assessment as not normal improved reliability, construct 
validity, and predictive validity of the Premie-Neuro classifications.  We concluded 
that a raw score cut-point of <90 may be used by the clinician to identify at-risk 
infants after 34 weeks PMA, but cautioned that this strict cut-point may result in a 
handful false-negatives.  Thus, preterm infants with borderline raw scores, ranging 
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from 90-99, should be closely monitored to ensure that neurological abnormalities do 
not emerge in those babies. 
In summary, this body of work is the first to show that the psychometric 
properties of the Premie-Neuro raw scores meet reliability and validity criteria for 
clinical use in the fragile, highly variable preterm infant population.  Although 
Premie-Neuro classifications based on raw score cut-points recommended by the 
assessment’s authors may not be reliable and valid, the present study proposes a new 
set of cut-points that may be used by the clinician to reliably classify a preterm 
infant’s assessment as normal, abnormal, or questionable.  These findings may have 
important implications for clinical practice in the NICU, as we have shown that 
clinicians now have access to a psychometrically sound assessment that may be 
administered repeatedly throughout an infant’s NICU stay—the  Premie-Neuro.  Our 
proposed guidelines for interpreting Premie-Neuro assessments as normal, abnormal, 
or questionable may be used by clinicians to identify at-risk babies who will benefit 
from specialized early intervention services and/or close post-term follow-up.   This 
has potential to improve effectiveness, efficiency, and outcomes of early intervention 
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 The United States Department of Health and Human Services reports that, in 
2006, 12.8% of all infants born in the United States were born preterm.  The rate of 
preterm births—defined as birth prior to 37 completed weeks gestational age (GA)—
has increased 20% since 1990 and 36% since 1980 (1).  The cause of this increase is 
unknown.  Prematurity is one of the leading causes of infant death and major 
disabilities such as cerebral palsy and mental retardation (1, 2).  Advances in neonatal 
care, including the introduction of antenatal steroids and postnatal surfactant, led to 
improved survival rates among preterm infants through the 1990s.  However, this 
increase in survival rate was accompanied by an increase in the number of preterm 
infants with major medical complication and poor neurodevelopmental outcomes (2-
5).  Over the last decade, continued improvements in medical care have led to 
improved outcomes of preterm infants, and the proportion of preterm infants with 
neurodevelopmental deficits, although not declining, has not risen (6, 7).  However, 
due to the rising numbers of preterm birth and improved awareness and methods of 
detection, there continues to be increasing numbers of preterm children with 
identified neurodevelopmental disability and/or delay.  During their stay in the 
neonatal intensive care unit (NICU) and in the first years of life, preterm children are 
often provided early intervention services such as speech, physical, or occupational 
therapy.  However, research is unclear whether these types of early intervention 
services are effective in improving long-term outcomes—particularly neuromotor 
outcomes—in preterm children who receive such services simply because they are 
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preterm (8-11).  Some studies suggest that motor interventions are effective in 
improving outcomes when they are aimed only at those preterm infants who are 
identified as high-risk using a standardized assessment (12, 13).  Thus, there is a 
growing need for clinical neurological assessment tools that will allow health care 
providers to reliably identify preterm infants most at-risk for neurological 
abnormality and potential disability so that those infants may be selectively referred 
for early intervention physical therapy services, avoiding over-utilization of services 
by preterm children who are not at-risk. 
 Currently, there are a handful of clinical neurological assessment tools 
available for use with preterm infants in the NICU, but there is no agreed-upon “gold 
standard” for neonatal neurological evaluation.  Available assessments can be lengthy 
to administer, require hours, weeks, or even months of administrator training, and/or 
cannot be given to children less than 30-32 weeks post-menstrual age.   This makes 
them very impractical for use by clinicians who desire an assessment tool that 
requires minimal infant handling and can be given quickly and repeatedly from birth 
to term, even for those infants who are born as early as 23-24 weeks gestational age.  
The Premie-Neuro—a new standardized neurological assessment tool developed by 
Donna Daily, MD—is unique in that it requires no special training for neonatal care 
providers and can be given in approximately 10 minutes to children ages 23 through 
37 weeks post-menstrual age (PMA) (14).  The work presented in this dissertation 
will describe the reliability and validity of the Premie-Neuro.  In this study, we 
examine interrater and test-retest reliability of the Premie-Neuro.  We also determine 
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whether the Premie-Neuro can discriminate between groups of infants who differ in 
terms of risk for neurodevelopmental delay and disability, and whether performance 
on the Premie-Neuro in the NICU can predict neurological and neuromotor 
performance at term and 3 months adjusted age.  Finally, we suggest raw score cut-
points that can be used to identify neurologically abnormal or questionable infants 
who may benefit from further examination and/or referral for early intervention 
services.  This work has implications for clinical assessment of preterm infants and 
will impact clinical decision-making when determining which infants require further 




Prematurity is defined as birth prior to 37 weeks completed gestation.  The 
preterm birth rate in the U.S. has been increasing steadily for the last several decades.  
Since 1990, the rate of moderately preterm (less than 34 weeks gestation) and very 
preterm (less than 32 weeks gestation) births has risen modestly, but the rate of late 
preterm birth (34-36 weeks gestation) has increased sharply (1).  Late preterm birth 
now accounts for approximately 60-70% of all preterm births (15).  Increasing 
multiple births has no doubt contributed to the rise in preterm births.  However, the 
preterm birth rate for singletons is also rising—11.1% of singletons were born 
preterm in 2006—so multiple births cannot be solely responsible for the trend. The 
rate of preterm birth is highest for black infants (18.5%).  The preterm rate for 
Hispanic births is 12.2% and 11.7% for non-Hispanic white births (1).   
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Approximately 30% of preterm births are medically indicated, usually due to 
maternal or fetal infection.  40-45% of preterm births occur following spontaneous 
preterm labor and 25-30% following premature rupture of membranes.  Although 
there are a number of maternal risk factors associated with preterm birth—including 
black race, short interpregnancy interval, low pre-pregnancy body mass index, 
previous preterm delivery, vaginal bleeding, stress and depression, smoking, 
intrauterine infection, and biological and genetic markers—a precise cause of preterm 
birth cannot be determined in most cases (15).   Until the causes of prematurity are 
better understood, it is likely that the preterm birth rate will continue to rise.   
 
1.3 Neuromaturation and mechanisms for brain injury in the preterm infant 
 
Neuromaturation—the development of the central nervous system (CNS)—is 
a dynamic process, dependent not only upon a preprogrammed genetic progression, 
but also upon the interaction between a fetus or infant and his environment.  Genetic 
processes ensure that early brain development in all humans follows the same 
predictable sequence.  However, intrauterine and extrauterine experiences result in 
individual variability in the developing brain (16, 17).  
In the first several weeks of gestation the neural plate—which eventually 
gives rise to the central nervous system—is formed.  Shortly after, neuroblast 
proliferation and neuronal migration, aggregation, and differentiation begin.  At 
approximately 8 weeks gestation, the first layer of the cortical plate is in place and the 
first synapses are seen (17, 18).  It is about this time that the earliest primitive 
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reflexes—such as rooting and grasp—emerge (16).  Neurons continue to migrate and 
aggregate, forming deeper cortical layers as gestation progresses.  By 8 months GA, 
cortical layers resemble that of older children.  During the third trimester of 
pregnancy—as the neurons reach their final positions—dendritic growth and synapse 
formation accelerate as each cortical neuron forms approximately 1,000 synaptic 
connections (19).  From 28 weeks PMA, synaptic density increases as much as 6 
times until it peaks as early as 3 months post-term in sensory areas such as the visual 
and auditory cortices and as late as 15 months post-term in the prefrontal cortex (18).   
In the second half of gestation, beginning at approximately 24 weeks GA, 
myelination of the central nervous system begins (17).  Myelination of the lower, 
subcortical motor system progresses upward from the spinal cord between 
approximately 24 and 32 weeks GA.  During this time, reflexes become stronger and 
flexor tone develops in a caudocephalic direction.  At 32 weeks GA, myelination of 
the higher corticospinal pathways begins in the pons, progressing down to the spinal 
cord and up to the cortex.  Development of these higher motor pathways suppresses 
the lower motor system, resulting in a decrease in the dominance of involuntary 
reflexes and an increase in head and trunk control and voluntary movements (16).  
Myelination continues after birth—reaching peak velocity between birth and one year 
as infants develop postural reactions and fine motor control—and persists well 
beyond the 3rd decade of life (16-18).   
Ironically, although normal rapid myelination occurring around the time of 
birth is necessary for healthy brain development, it also makes the neonatal brain 
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particularly susceptible to injury.  Oligodendrocytes—the cells responsible for 
myelination in the CNS—are extremely vulnerable to hypoxia (17, 19).  This is more 
problematic for preterm infants, the youngest of whom may be born just as 
myelination is beginning, because immature oligodendoglial precursor cells are 
especially susceptible to injury.  This problem is compounded by the fact that, in the 
preterm infant, blood supply to cerebral white matter is incomplete and regulation of 
cerebral blood flow is impaired (17, 19, 20).  Thus, damage to the white matter 
around the ventricles of the brain is common in preterm infants, an injury known as 
periventricular leukomalacia (PVL).  PVL is the primary form of brain injury in the 
preterm infant and is associated with symmetrical damage to the internal capsule (20, 
21).  This results in the most common form of cerebral palsy in preterm children—
spastic diplegia—in which spasticity is present in all four limbs but is dominant in the 
lower extremities (3).   
The other major form of brain injury frequently associated with preterm 
birth—and one that is frequently associated with PVL (22)—is periventricular 
hemorrhage/intraventricular hemorrhage (PVH/IVH).  The incidence of PVH/IVH 
has declined over the past several decades, but is still estimated to occur in 
approximately 20-25% of all preterm births.  It is most prevalent in infants born at 
less than 32 weeks GA (21).  PVH/IVH can be caused by hypoxic ischemic 
encephalopathy, respiratory distress, or circulatory problems, and is graded I, II, III, 
or IV based on localization of the bleeding, the amount of blood in the ventricles and 
degree of ventricular distension (grade I is mildest, while grade IV is most severe).  
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The risk of neurodevelopmental disability increases with increased grade of 
PVH/IVH (23).  Over 90% of children with a grade IV intraventricular hemorrhage 
will be diagnosed with a neurodevelopmental disability—such as cerebral palsy—
later in life (21).  
It is important to note that many infants with neurological sequelae do not 
have identifiable brain injury, such as PVL or PVH/IVH, on cranial ultrasound (24).  
In a preterm baby, CNS maturation designed to take place in the womb instead occurs 
in an extrauterine environment and this process may not be trouble-free, even in the 
absence of brain injury. Thus, neurodevelopmental disability and delay seen in some 
preterm infants may be the result of abnormal brain development rather than an 
identified brain injury or lesion (25).   Conversely, many preterm children with white 
matter lesions have no neurological abnormalities.  This is probably due to the 
incredible plasticity and adaptability of the immature brain, which—as described in a 
2007 review by Wyatt—may occur through “remodeling of existing white and grey 
matter regions, the refinement and selection of dendritic connections, the rerouting of 
white matter tracts to circumvent obstructions, and the development of alternative 
cortical processing strategies” (19).  Although cranial ultrasound and MRI give the 
clinician important information on brain structures, they do not provide insight on 
neurological function.  Thus, the results of neuroimaging must be combined with 
clinical neurological assessment to enhance clinical decision-making. 
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1.4 Neurodevelopmental outcomes in preterm infants 
As the number of preterm births in the United States has risen, there have 
been significant advances in high-risk obstetric and neonatal care.  As a result, 
through the 1990s, preterm infant mortality rates decreased and the limits of viability 
lowered to approximately 23-24 weeks gestational age (2, 4, 5, 7, 26).   As survival 
rates improved, there was little change in the incidence of major medical 
complications—such as brain injury, necrotizing enterocolitis, chronic lung disease, 
and poor postnatal growth—predictive of future disability in preterm infants, and the 
number of preterm children with poor neurodevelopmental outcomes rose sharply (2, 
3, 5, 27, 28).  In the past decade, neonatal morbidities have begun to decrease, largely 
in part to improved medical care, and there has been a leveling off or perhaps even a 
slight decrease in the proportion of preterm children with significant 
neurodevelopmental impairment and cerebral palsy (6, 7).  However, due to 
increasing preterm birth rates as well as improvements in detection of minor 
neurological dysfunctions such as learning disabilities, behavioral problems, and 
developmental coordination disorder, the number of preterm children with identified 
neurodevelopmental dysfunction continues to rise (3, 29-40).   
Cerebral palsy (CP)—one of the most severe and disabling consequences of 
prematurity—results from neurological lesions, such as intraventricular hemorrhage 
or periventricular leukomalacia, suffered prior to, during, or soon after birth (20).  
Studies show that the prevalence of CP in preterm infants varies greatly with factors 
such as gestational age, birth weight, and medical complications.  Depending upon 
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these factors, CP is diagnosed in anywhere from 7% to over 20% of preterm infants 
(3, 20, 27, 32, 37, 41-45).  The developmental course after brain injury in preterm 
infants is highly variable and poorly understood.  Transient neurological signs—such 
as dystonia—result in high rates of false-positive results on early neurological 
assessments (children who are neurologically normal test in the abnormal range).  To 
avoid misdiagnosis, most children are not labeled as having CP or other major 
neurological disorders until they are nearly 2 years old.  Children with mild forms of 
CP may not be diagnosed until even later in childhood (3).  Although most preterm 
infants will not be diagnosed with CP, many demonstrate moderate neuromotor 
dysfunction or exhibit significant cognitive deficits by school age (3, 6, 35, 36, 41, 
43, 45-47). 
There has been growing interest in “high prevalence/low severity” 
neurological dysfunction—or “soft” signs—in children born prematurely.  These 
more subtle dysfunctions occur in high rates in children who were preterm, and 
include learning disabilities, minor motor impairment such as developmental 
coordination disorder, subnormal IQ, and social-emotional and behavioral problems 
(3, 21).  In fact, studies have shown that the majority of preterm infants have below-
average fine and gross motor skills at school age, and they tend to score consistently 
lower on educational testing compared to their term counterparts (3, 30, 33, 34, 38, 
39, 47-52).  Because these minor dysfunctions often involve difficulties with higher-
level skills, they are usually not recognized until school age, when cognitive and 
developmental demands are higher than in early childhood (21, 31).  Of particular 
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interest to physical therapists is the recent increase in the incidence of developmental 
coordination disorder (DCD) among preterm children.  Recent studies have shown 
that anywhere from 10-31% of extremely low birth weight or very preterm children 
have DCD, which is characterized by poor motor performance in the absence of 
global developmental delay or neurological signs associated with CP (50, 52).  Like 
other low-severity dysfunctions, DCD is often not diagnosed until school age, if ever, 
and is often seen in otherwise “normal” preterm children (53).  This begs the question 
of whether there may be early, transient neurological signs that could be assessed in 
preterm babies that would provide an early indication of this future mild motor 
dysfunction. 
 
1.5 Predictors and risk factors for poor neurodevelopmental outcomes 
 
 Prediction of preterm infant outcomes remains one of the most challenging 
aspects of neonatal care.  Although studies have identified some risk factors and 
predictors of poor developmental outcomes in groups of infants, individual outcomes 
are much more difficult to predict.  This is in part because—in addition to perhaps 
more obvious predictors of poor neurodevelopmental outcomes such as abnormal 
cranial ultrasound or abnormal neurological exam—there are several non-
neurological factors such as gestational age at birth, gender, and respiratory history 
that influence risk.   
 Neuroimaging and neurological examination results are two of the most 
studied risk factors for future neurodevelopmental delay.  Multiple studies have 
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shown that infants with grades III or IV IVH or PVL on cranial ultrasound have a 
significantly greater risk of moderate neuromotor dysfunction or more severe deficits 
such as cerebral palsy (21, 23, 28, 46, 47, 54, 55).  However, as described in Section 
1.3, there are many infants with normal cranial ultrasound findings that go on to 
exhibit neurodevelopmental disabilities and delays and there are a large proportion of 
infants with abnormal cranial ultrasound findings that have little to no functional 
neurological deficits (19, 24, 25, 49).  In 2005, Rademaker and colleagues reported 
that, in preterm infants, MRI showed more subtle white matter abnormalities and 
correlated more strongly with outcomes than cranial ultrasound.  This suggested that 
cranial ultrasound, which is much more commonly used in the NICU than MRI, may 
not be sensitive enough to detect brain lesions in all preterm babies (56).  But it is 
also possible that developmental outcomes have as much to do with brain 
development and adaptation as with specific brain lesions. Thus, although results of 
neuroimaging may provide one model of prediction, those results should not be 
viewed as diagnostic (43).  Recent studies have suggested that clinical neurological 
examination may be as significant as neuroimaging in predicting developmental 
outcomes and that the two should be combined to optimize prediction of poor 
neurodevelopmental outcomes (57, 58). 
 There are a number of non-neurological factors that have also been found to 
influence risk.  Infants born at younger gestational ages (GA) have worse 
neurodevelopmental outcomes than older preterm or term infants (3, 21, 43, 59).  
However, it is difficult to determine whether the increase in risk is truly due to 
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decreased birth GA or due to medical complications frequently associated with 
younger preterm babies.  Bronchopulmonary dysplasia—defined as oxygen 
dependence at 36 weeks PMA—is one such complication that has been highly 
associated with poor outcomes in preterm infants.  Infants with bronchopulmonary 
dysplasia have demonstrated increased rates of developmental delay through 18 
months adjusted age in a variety of studies (28, 60, 61).  This may be due to the 
increased risk of hypoxia in infants with respiratory distress or because respiratory 
insufficiency may be an indicator of overall sickness, which is more likely to result in 
poor outcomes.  Other potential risk factors for neurodevelopmental delay—
according to the literature—include retinopathy of prematurity, male sex, low birth 
weight, and low Apgar scores (24, 28, 31, 33, 37, 38, 46, 50, 62, 63).  Much of the 
evidence contends that the best prediction models do not look at risk factors in 
isolation, but rather consider a combination of some or all neurological and non-
neurological risk factors (21, 28, 54, 62). 
 
1.6 Effects of early intervention  
 
 While in the NICU or upon NICU discharge, preterm infants are frequently 
referred for early intervention services such as physical, occupational, or speech 
therapy.  A 2004 study by Clements and colleagues revealed that, among preterm 
children in the state of Massachusetts, the cost of early intervention services averaged 
$5393 per infant born at 24-31 weeks gestational age (GA) and $1578 per infant born 
at 32-36 weeks GA, compared to just $725 per term infant (64).   Despite the large 
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amounts of dollars that states like Massachusetts are spending on habilitation of 
preterm children, there is conflicting evidence whether early intervention services are 
effective in improving outcomes in this population (8-10).   
 A recent meta-analysis by Spittle and colleagues reviewed 16 randomized 
controlled trials of early intervention that began in the first year of life for preterm 
infants, and found that early intervention improved cognitive outcomes in infancy and 
preschool but not at school age.  Early intervention had no effect on motor outcomes 
at any age (11).  This seems to be discouraging news for early interventionists 
working to improve motor outcomes in preterm infants.  However, it is important to 
note that many of these studies recruited only low-risk infants or included very broad 
samples of preterm babies (i.e. very low birth weight or birth prior to 33 weeks 
gestation age) without regard for risk and, therefore, possible need for these services. 
Two studies have looked at the efficacy of early motor interventions specifically 
provided to high-risk infants, and both found positive effects. 
 In 1994 Girolami and Campbell (12) recruited infants born at ≤ 35 weeks GA 
who also had at least one of the following complications:  5-minute APGAR ≤ 5, 
intraventricular hemorrhage, seizures, respiratory distress syndrome, respiratory 
arrest, birth weight <1000 grams, central nervous system depression or irritability, 
asphyxia, mechanical ventilation, or thermal instability.  These babies were then 
tested using the Neonatal Behavioral Assessment Scale (NBAS) and were only 
included in the study if they demonstrated at least 3 abnormal or asymmetrical 
reflexes.  Identified at-risk infants were randomized into control and treatment 
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groups.  Infants in the control group received no physical therapy intervention in the 
NICU.  Infants in the treatment group received neurodevelopmental treatment (NDT)-
based intervention twice per day for 7-17 days.  A full-term comparison group 
received no intervention. At the end of the study, the preterm treatment group 
performed significantly better on the supplemental motor test (SMT), a test designed 
for the study to assess functional postural control.  This suggests that high-risk 
preterm infants may benefit from physical therapy in the NICU. 
 Lekskulchai and Cole (13) published a similar study in 2001, but looked at a 
larger group of preterm infants and measured outcomes over a longer time period.  
For their study, they tested all participants using the Test of Infant Motor 
Performance (TIMP).  Infants with scores less than 67 were designated as “at-risk” 
and randomly assigned to a treatment group or control group.  The control group did 
not receive intervention and the treatment group received developmental physical 
therapy intervention from term to 4 months adjusted age. Infants with scores of 
greater than 67 were considered to be not at-risk and were included in a comparison 
group that received no intervention.  At term, both the intervention and control groups 
had worse TIMP scores than the comparison group.  However, by four months 
adjusted age, the intervention group scored significantly higher on the TIMP than 
both the preterm control group and the comparison group.  The results of this study 
strengthen the argument that early intervention physical therapy services may indeed 
be beneficial when targeted at high-risk preterm babies. Reliable and valid clinical 
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neurological assessment tools would assist the clinician in identifying those high-risk 
babies that would be most likely to benefit from early intervention services. 
 
 
1.7 The role of clinical neurological assessment in identification of at-risk infants 
 
The neonatal neurological examination is designed to measure the function 
and maturity of the central nervous system.  Most standardized neonatal neurological 
examinations include items that assess posture, movement, active and passive muscle 
tone, primitive reflexes, and/or responsiveness to sensory stimuli.  Although 
physicians frequently assess these items in a non-standardized fashion as part of 
routine neonatal care, use of a standardized assessment tool has many benefits.  
Standardized neurological assessments may aid the clinician in establishing a baseline 
for neurological function and, when administered serially, may reveal infants with 
transient, resolving neurological abnormalities versus infants with persistent 
abnormalities.  Furthermore, standardized neonatal assessment tools may—if 
psychometrically sound—be used as an outcome measure for research purposes (65).  
Recent studies have shown that standardized neonatal neurological assessments in the 
NICU are effective in predicting neurodevelopmental outcomes, particularly when 
used in combination with neuroimaging results (57, 58).  Predictive standardized 
assessment tools can aid the clinician in clinical decision-making when making 




Currently, a number of clinical neurological assessments for preterm infants 
are available for use by neonatal health care providers and researchers. However, 
there is no agreed-upon “gold standard” for preterm infant neurological assessment.  
Psychometric soundness is not well established for many assessments for preterm 
infants.  This is largely because—in preterm babies—autonomic instability leads to 
disorganized state- and self-regulation, resulting in inconsistent, sometimes abnormal 
motor control and neurobehavior (66).  Often, even when reliability and validity of 
standardized assessments seem to be clinically significant, wide variations both 
between and within babies make statistical significance nearly impossible to achieve.  
This is particularly true for very sick preterm babies and/or those at younger post-
menstrual ages, when the CNS is stressed and immature and self-regulation is 
particularly poor.  As sickness resolves, babies become more medically stable, and as 
they approach term-adjusted age, functional neurological status is less confounded 
with physiological status (67) and results of standardized testing may become more 
consistent.  As a result, researchers studying psychometrics of standardized 
neurological assessment tools frequently solve the problem of infant variability and 
relatively low statistical relationships by testing only older preterm babies and/or low-
risk, “healthy” preterm infants with few or no major medical complications or risk 
factors.  However, this practice results in tests that are validated on only a fraction of 
infants who may be admitted to the NICU and speaks little to the clinical significance 
of such assessments.  When sicker or younger preterm infants are studied, lower 
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correlations may be used to represent meaningful, clinically significant—although not 
necessarily statistically significant—relationships. 
While tools that do have established psychometric properties are useful for 
research purposes, they are often not clinically useful as they may take a great deal of 
time to administer and/or score and they often require extensive training.  For 
example, the Assessment of Preterm Infant Behavior (APIB) is a neurobehavioral 
assessment for preterm infants who can be handled on room air (68).  The authors of 
the APIB report that it has a very sound theoretical and scientific basis and that 
interrater reliability is easily established in trained examiners (69).  Studies on the 
APIB have shown acceptable sensitivity and construct validity.  However, it requires 
8-10 months of training for the advanced clinician and takes up to 60 minutes to 
administer, 30 minutes to score, and 3 hours to write a summary report (68, 69).    
The Neurobehavioral Assessment of the Preterm Infant (NAPI) requires that 
examiners view a training videotape, and it takes only about 30 minutes to administer 
(68).  The NAPI has well-documented reliability and validity.  However, it can be 
administered only on infants at 32 weeks PMA or later (70-72).  This limits its ability 
to be used for serial assessment of very preterm infants born before 32 weeks GA.   
The Test of Infant Motor Performance (TIMP) can also be administered 
beginning at 32 weeks PMA, so its use is limited in younger preterm babies.  It 
requires 36 minutes to administer and score (73).  The TIMP is a relatively new 
assessment, and its psychometric properties continue to be studied.  It appears to have 
good test-retest reliability and it is responsive to change over time.  However, there 
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are questions about the construct validity of the TIMP as there is conflicting research 
on whether it discriminates among infants at varying risk for poor neurological 
outcomes (73-75).   
The Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) is 
another relatively new neurological assessment for preterm infants.  It was originally 
designed for a study on prenatal drug exposure (76).  The NNNS requires certification 
through a special training program, and the test can be completed in less than 30 
minutes on infants at 30 weeks PMA or later (76, 77).  Test-retest reliability has been 
established in preterm infants. However, validity has only been established in term 
infants (76).    
 
1.8 The Premie-Neuro 
 
 The Premie-Neuro is a standardized clinical neurological assessment for 
preterm infants 23-37 weeks PMA.  It consists of 3 subtests, each containing 8 items.  
The Neurological subtest contains items that assess primitive reflexes such as plantar 
or palmar grasp, muscle tone (i.e. popliteal angle and scarf sign), and movement type.  
The Movement subtest tracks the rate per minute of behavioral signs of stress and 
avoidance behavior such as yawning, color changes, and limb movements.  Finally, 
the Responsiveness subtest assesses active tone (head and trunk control), alertness, 
and responsiveness.  Because the Responsiveness subtest involves changing the 
position of the infant, it is not recommended for infants who are less than 28 weeks 
 
 20
PMA or who are on a ventilator.  Thus, for these more immature and sicker babies, 
only the Neurological and Movement subtests are administered (78).   
 The Premie-Neuro was first described in 2005 by Daily and Ellison, who 
identified few available methods for assessing brain function in preterm infants, 
particularly in those born at less than 28 weeks gestational age.  They constructed the 
tool to be “acceptable to the clinician in terms of the stress it places on the sick or 
convalescing newborn, the time required for assessment, the clarity of items, and the 
simplicity of scoring” (14).  In their only published paper on the tool, Daily and 
Ellison described the construction of the 24-item assessment from 75 original items.  
Internal consistency of the tool ranged from 0.73-0.82 (14).  A pilot study of the 
Premie-Neuro reported significant predictive validity of the tool at term and 6-8 
months adjusted age (79).   
 The Premie-Neuro is quick to administer, requiring less than 10 minutes.  It 
does not require extensive examiner training and can be done with minimal 
disturbance of the infant, without removing him from his crib or isolette and without 
interfering with electronic monitoring or mechanical ventilation.  At this time, it is the 
only standardized neonatal assessment that can be safely administered on infants as 
young as 23 weeks PMA (14, 78). 
 
1.9 Significance of presented work 
 
Repeated neurological assessments of preterm infants are critical in 
identifying neurological abnormalities and determining if those abnormalities persist 
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or resolve (16, 68).  Unfortunately, many currently available assessments are not 
optimal for repeated examination because of the time required to administer and/or 
the limited age range in which the test may be performed.  The Premie-Neuro is 
designed to overcome these problems, making it a promising tool for serial 
neurological assessment in the NICU.  Administration of the Premie-Neuro does not 
require extensive training.  Healthcare providers with experience handling and 
observing preterm infants may be trained by simply reviewing the administration 
manual and observing the testing procedure.  The Premie-Neuro can be administered 
in less than 10 minutes, requiring much less time than many comparable assessment 
tools and requiring much less handling and potential stress to the infant.  The Premie-
Neuro can be safely completed on an infant as young as 23 weeks PMA, even if that 
infant is on a ventilator and/or requires electronic monitoring (14).  This means that 
the Premie-Neuro can be administered on even the youngest and sickest infants, and 
can continue to be used as the infant’s health improves and the infant reaches term 
adjusted age (37 weeks PMA).  Despite these unique features of the Premie-Neuro, it 
is not yet widely used because—until now—the psychometric properties of the 
assessment have not been established.  In the present study, we will present evidence 
that Premie-Neuro raw score is reliable and valid. These findings may change the way 
neonatal neurological assessment is conducted in the NICU. 
The present study may change the way early intervention services are 
provided in the NICU and following NICU discharge.  Currently, there are few 
available methods to identify at-risk infants in the NICU, so developmental 
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interventions are often postponed until evidence of a delay or disability is undeniable.  
However, there is consensus that one of the most rapid periods of brain growth and 
development is the last 3 months preterm through the first several months post-term 
(8, 16, 19).  Although there is conflicting evidence whether early intervention 
services are effective in improving outcomes in all babies, it is difficult to analyze 
these studies due to the large variability in the subject populations studied, methods of 
intervention used, and outcome measures.  There are several well-conducted studies 
that show clear benefits of developmental care (such as NIDCAP) and task-specific 
training for low-risk preterm babies, as well as a positive effect of physical therapy 
interventions selectively administered to high-risk babies (8, 12, 13, 80-82).  Perhaps 
the evidence will strengthen as we begin asking the right questions or using 
appropriate outcome measures, but it is clear that interventions provided for high-risk 
babies in the first months of life can impact functional outcomes.  The presented work 
may impact utilization of early intervention services for preterm babies in two ways.  
First, in Chapter 4, we will suggest modifications of Premie-Neuro cut-points used to 
classify infants as normal or not normal.  This classification system will allow earlier 
identification of at-risk infants—those who repeatedly score in the not normal 
range—so that those babies may be evaluated further and/or targeted for intervention 
services at earlier ages.  This will also reassure parents and clinicians of infants who 
are repeatedly classified as normal, and may prevent over-utilization of services for 
infants who do not demonstrate any functional neurological abnormalities.  Second, 
this work will allow clinicians and researchers the ability to quantify neurological 
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development at younger ages than ever before so that the effectiveness of 
interventions provided as early as 23 weeks PMA in the NICU may be monitored or 
formally studied. 
 
1.10 Specific aims and statement of hypotheses 
 
The purpose of this presented work was to determine the reliability and 
validity of the Premie-Neuro for preterm infants in the neonatal intensive care unit 
(NICU).   
 
Specific Aim 1:  Determine the reliability of the Premie-Neuro in preterm infants in 
the NICU.   
Reliability is a measure of the repeatability of a test when given under 
identical conditions (65).  High reliability does not necessarily indicate a “good” test, 
but does indicate that there is minimal error resulting from variability between or 
within raters (83).  Preterm infants demonstrate large variations in neurological 
function while in the NICU, which often proves challenging when attempting to 
identify high-risk infants and predict neuromotor outcomes (3).  It is important that a 
standardized clinical neurological assessment have acceptable interrater and test-
retest reliability to ensure that variation in scores is due to true variation in the 
infant’s neurological status and not due to error variance of the examiner or the 
instrument.  Thus, we hypothesized that interrater reliability of Premie-Neuro raw 
score would be high (ICC≥0.80) and that one-day test-retest reliability of Premie-
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Neuro raw score would be high (ICC≥0.73).  We further hypothesized that Premie-
Neuro classifications (normal, questionable, and abnormal) would demonstrate at 
least moderate agreement (Kappa >0.40) over a one-day period, and that Premie-
Neuro classifications would be stable over at least two consecutive weeks, with 
infants remaining in one classification for at least 60% of all assessments. 
 
Specific Aim 2:  Establish construct validity and responsiveness of the Premie-
Neuro in preterm infants in the NICU.   
 Validity refers to the extent that an instrument measures what it is intended to 
measure (65). Responsiveness describes a test’s ability to detect clinically important 
change (68, 75, 84). We believed that the Premie-Neuro would detect differences 
between two groups of infants known to be at high and low risk for neurological 
insult and that it would be responsive to different rates of neuromaturational change 
in infants in these groups.  Specifically, we hypothesized that Premie-Neuro raw 
scores would be significantly lower (worse) for high-risk infants, and that low-risk 
infants’ scores would remain unchanged while high-risk infants’ scores decreased 
over time.  We further hypothesized that a larger proportion of high-risk infants 
would be classified as neurologically questionable or abnormal versus low-risk 
infants.  Significance was set at p<0.05. 
 Construct validity of the Premie-Neuro was also analyzed by determining if 
characteristics that are associated with poor neurological outcomes are also associated 
with Premie-Neuro scores.  We hypothesized that low GA at birth, presence of CNS 
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injury and diagnosis of bronchopulmonary dysplasia (BPD)—characteristics that are 
associated with poor neurodevelopmental outcomes (23, 24, 28, 37, 43, 54, 55, 59-
61)—would be significant (p<0.05) predictors of Premie-Neuro neurological scores 
and classifications. 
 
Specific Aim 3:  Estimate the predictive validity of the Premie-Neuro in preterm 
infants in the NICU.   
 Predictive validity is the ability of performance measured by one instrument 
to predict future performance on another instrument that measures the same construct 
(65, 83).  This type of validity is particularly relevant to clinicians in the NICU as it 
allows them to make a neurological prognosis, identify appropriate interventions, and 
plan for follow-up care.  In this study, we hypothesized that Premie-Neuro scores 
obtained before 38 weeks PMA would have a positive and fair (>0.25) correlation 
with NeoNeuro scores at term and Infanib and AIMS scores at 3 months adjusted age. 
We further hypothesized that there would be a significant (p<0.05) relationship 
between Premie-Neuro classifications obtained in the NICU and NeoNeuro 




 The last 3 months of gestation may represent a critical period in brain 
development as it is a time of rapid synaptogenesis and myelination (16-19).  
Unfortunately for the preterm infant, this time is spent in the NICU rather than the 
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womb.  It is true that the preterm infant brain is more susceptible to lesions such as 
intraventricular hemorrhage and periventricular leukomalacia, but—even in the 
absence of these lesions—preterm infants exhibit neurodevelopmental delay and 
disability resulting from suboptimal CNS development (19-21, 25, 27).  Although 
neuroimaging provides invaluable information on brain structure, this information 
must be combined with clinical data, such as results of standardized clinical 
neurological assessments, to determine brain function, identify at-risk infants, and 
improve prediction of those babies who will have poor neuromotor outcomes (57, 
58).  The findings of the presented work may allow clinicians to reliably assess 
preterm infants and combine those findings with neuroimaging results and clinical 
data to identify at-risk infants, make decisions about referring for specialized early 










The Premie-Neuro:   





 There are few methods available for clinicians to assess the functional 
neurological status of the newborn.  As more preterm infants continue to live, there is 
a growing need for reliable and valid clinical neurological assessment tools to assist 
the clinician in targeting preterm infants at risk for developmental delay.  The purpose 
of the present study was to determine the reliability and validity of the Premie-Neuro, 
a new clinical neurological test for preterm infants.  In this study, infants were 
assessed twice—24-72 hours apart—using the Premie-Neuro.  One of these 
assessments per infant was observed and scored by a second examiner.  Infants 
continued to be administered the Premie-Neuro weekly through 37 weeks post-
menstrual age or discharge from the NICU.  At discharge, infants’ medical charts 
were reviewed to determine medical risk factors for neurodevelopmental delay.  
Infants were categorized as “high” (high risk, HR) or “low” risk (low risk, LR) for 
neurodevelopmental delay using the Neurobehavioral Risk Scale (85).   The Premie-
Neuro had fair to moderate interrater and one-day test-retest reliability.  Premie-
Neuro classifications were stable across weeks.  Premie-Neuro scores were higher in 
the LR group.  Scores tended to worsen over time in the HR group but not in the LR 
group.  Infants who were not oxygen-dependent at 36 weeks post-menstrual age were 
more likely to be classified as neurologically “normal” using the Premie-Neuro.  
Oxygen dependence at 36 weeks post-menstrual age and CNS abnormalities (grades 
III and IV intraventricular hemorrhage or periventricular leukomalacia) were 
significant predictors of Premie-Neuro score.  These data suggest that the Premie-
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Neuro raw scores have acceptable reliability and validity for clinical use with preterm 
infants.  Premie-Neuro classifications should be interpreted with care.  The Premie-
Neuro may be used as an adjunct to clinical assessment to identify preterm infants at-





 Over 12% of infants in the United States are born too soon.  The rate of 
preterm births—defined as birth prior to 37 completed weeks gestational age (GA)—
has increased significantly over the last several decades (1).  Advances in modern 
medicine, including the introduction of antenatal steroids and postnatal surfactant, led 
to improved survival rates among preterm infants through the 1980s and 1990s.  But 
increased survival was accompanied by increased neonatal morbidities, and the 
number of preterm infants with resultant neurological sequelae—such as cerebral 
palsy—rose through the mid- to late-1990s (2-5, 36).  Over the last decade, as 
survival rates have leveled off and medical care has improved, the proportion of 
preterm children with significant neurodevelopmental disability or delay has not 
increased (6, 7).  However, with rising rates of prematurity and improved detection of 
more subtle neurological disabilities, there continues to be large numbers of preterm 
children who may benefit from specialized care in the neonatal intensive care unit 
(NICU) and throughout childhood.  A recent review by Blauw-Hospers and Hadders-
Algra found that developmental care, such as the Newborn Individualized 
Developmental Care and Assessment Program (NIDCAP), improved outcomes 
among the general population of preterm children (8).  However, more specialized 
early interventions—such as physical therapy—do not seem to affect outcomes unless 
they are targeted specifically at preterm infants who have already been identified as 
at-risk for neurodevelopmental delay or disability (9, 10, 12, 13).  This suggests it 
may not be appropriate to refer a preterm infant for early intervention services simply 
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because he is preterm, and speaks to the growing need for clinical neurological 
assessment tools that would reliably identify high-risk infants, assisting the clinician 
in making appropriate referrals for early intervention and improving efficiency and 
avoiding over-utilization of these services. 
 Although there are a variety of assessment tools available for use in the 
preterm infant population, there is no agreed-upon “gold standard” for neonatal 
neurological evaluation.  Many tests are quite lengthy to administer, potentially 
placing prolonged stress on the infant.  Furthermore, many clinical neurological 
assessment tools require extensive examiner training and few are appropriate for 
infants younger than 30-32 weeks post-menstrual age (PMA).  It is crucial that health 
care providers have access to a clinical neurological assessment tool to identify high-
risk preterm infants in the neonatal intensive care unit (NICU) so that early 
intervention services can be initiated, if necessary, during the critical period of rapid 
brain maturation that occurs in the first months of life.  It is clinically important that 
such a tool requires minimal infant handling, contains items appropriate for all 
preterm infants in the NICU—even the tiniest infants who may be as young as 23 
weeks PMA—and is quick and relatively easy to administer.  The Premie-Neuro, a 
standardized neurobehavioral assessment tool developed by Donna Daily, MD, has 
the potential to fill this role (14).  
 The Premie-Neuro consists of 3 subscales:  Neurologic, Movement, and 
Responsiveness.  Each subscale consists of eight items for a total of 24 items on the 
full Premie-Neuro (Table 2.1).  The Neurologic subscale includes reflexes and 
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measures of passive tone such as palmar and plantar grasp, arm recoil, and popliteal 
angle.  The Movement subscale requires that the examiner track and calculate the rate 
(per minute) of spontaneous limb movements, color changes, startles, and other 
physiologic and behavioral stress signs during the examination. The Responsiveness 
subscale includes measures of active tone, head and neck control, alertness, and 
responsiveness when the infant is placed in a variety of positions such as supported 
sitting and ventral suspension.  Infants who are 28 weeks PMA or younger or who are 
on a ventilator are only administered the Neurologic and Movement subscales of the 
Premie-Neuro, a total of 16 items.  Infants older than 28 weeks PMA and not on a 
ventilator are administered all 24 items in the 3 subscales.  Each item is assigned a 
score of one, three, or five based on the infant’s gestational age and performance on 
the item. Item scores are tallied and the infant is classified as neurologically normal, 
questionable, or abnormal based on raw score cut-points recommended by the 
Premie-Neuro authors in The Premie-Neuro Examination Instruction Manual (78). 
 In 2005, Daily and Ellison described the construction of the Premie-Neuro and 
reported its internal consistency to range from 0.73-0.82 (14).  A pilot study of the 
Premie-Neuro reported acceptable predictive validity at 6-8 months adjusted age (79).  
However—although the tool is in limited use—complete psychometric properties of 
this assessment, including reliability and validity, have not yet been established.  
Thus, the purpose of this study was to establish the interrater and test-retest reliability 







 Thirty-four preterm infants (mean gestational age at birth 29 ±3.67 SD weeks, 
BW 1343.18± 696.25 SD grams) were recruited from the NICU (Table 2.2).  In 
accordance with the Human Subjects Committee, each participant’s parent or 
guardian signed an institutionally approved parental consent form.  Infants were 
included in the study if they were born prior to 37 weeks gestation and were no more 
than 37 weeks PMA at the time of the first Premie-Neuro assessment.  Infants with 
major medical complications were included in the study if their physician agreed that 
they were medically stable enough to undergo clinical neurological assessment.  
Infants born at or after 37 weeks completed GA or with a known genetic disorder or 
major congenital anomaly were excluded from the study.  In order to demonstrate 
significance at a power of 0.80, a minimum of 10 infants was needed to test interrater 
reliability, and approximately 30 infants were needed for all other analyses.  
  
Procedure 
 Premie-Neuro testing began as soon as possible after obtaining parental 
consent.  Prior to each test, the infant’s physician or nurse was consulted to ensure 
that the infant was sufficiently medically stable to undergo hands-on assessment that 
day.  All Premie-Neuro testing was conducted at bedside by a physical therapist.  
Each infant remained in his or her crib or isolette during testing.  In order to minimize 
the potentially confounding effect of alert state, Premie-Neuro assessments were 
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conducted within the hour prior the each participant’s scheduled feeding time 
whenever possible.  Signs of physiological stress were monitored during testing.  
Testing was discontinued and/or canceled and rescheduled if the infant showed 
significant signs of stress—such as elevated heart rate or low oxygen saturation—
during the testing or was acutely ill the day of testing.  
 During the first week of the study, the Premie-Neuro was administered two 
times by the same examiner (Examiner 1, E1) 24-72 hours apart.  During the second 
assessment, a second examiner (Examiner 2, E2) observed the hands-on assessment 
and independently scored the Premie-Neuro.  E1 continued to administer the Premie-
Neuro approximately weekly (once every 5-9 days) through 37 weeks PMA or 
discharge, whichever occurred first.  
 At the time of enrollment in the study, each infant’s birth weight, sex, and 
gestational age at birth were obtained by reviewing the infant’s medical chart.  At 
discharge, the infant’s medical chart was reviewed to obtain the following 
information:  blood pH history, seizure activity, evidence of central nervous system 
injury, respiratory history (including need for mechanical ventilation), and history of 
hypoglycemia.  These data were used to calculate a Neurobiologic Risk Score 
(NBRS) (85, 86) for each infant.  Infants with a discharge NBRS of <5 were 
considered  “low risk”  (Low Risk Group, LR) and infants with a discharge NBRS of 
≥5 were considered  “intermediate/high risk” (High Risk Group, HR) for neurological 
injury and poor neurodevelopmental outcomes (85, 87).  Descriptive information for 




 Intraclass correlation coefficients (ICC) were calculated for raw scores 
obtained by E1 and E2 for the same assessment to estimate interrater reliability and 
for scores obtained by E1 on consecutive days to estimate short-term test-retest 
reliability of the Premie-Neuro.  Reliability of Premie-Neuro classifications (normal, 
questionable, or abnormal) was calculated using Kappa agreements.  Early sickness 
and autonomic instability in the young preterm infant can manifest as disorganized 
sensory and motor function (66).  Because of this, there is significant variability in the 
neurobehavioral status of preterm babies—both within and between infants—
particularly at young gestational ages (67).  Thus, in preterm infants, lower 
correlations—in the fair to moderate range—may be used to signify clinically 
important relationships.  For this study, reliability calculations were interpreted 
cautiously using Landis and Koch criteria:  <0.20 slight, 0.21-0.40 fair, 0.41-0.60 
moderate, 0.61-0.80 substantial, and 0.81-1.00 almost perfect (88).  Construct validity 
and responsiveness of the Premie-Neuro were assessed using a two factor (Group by 
Post-Menstrual Age) repeated measures ANOVA with Premie-Neuro raw score as the 
dependent variable.  Fisher’s exact test was used to determine if there was a 
significantly larger proportion of LR infants classified as normal on the Premie-Neuro 
versus HR infants at both the first and discharge Premie-Neuro assessments.  Logistic 
and linear regression analyses with stepwise elimination were used to determine if 
GA at birth, significant CNS injury (grades III or IV intraventricular hemorrhage, 
periventricular leukomalacia, residual ventriculomegaly, and intraparenchymal 
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periventricular echodensities) or oxygen dependence at 36 weeks were predictive of 
Premie-Neuro classifications and raw scores, respectively, at first and discharge 
Premie-Neuro assessments (2, 23, 28, 54, 55, 60, 61).   
 In accordance with the Premie-Neuro instruction manual (78), all infants were 
administered the Neurologic and Movement subscales of the test.  Infants older than 
28 weeks PMA and who were not on a ventilator at the time of testing were also 
administered the Responsiveness Subscale.  Thus, selected analyses were conducted 
for two subtests for all infants and for all three subtests only for infants who were 
administered the full Premie-Neuro. Analyses were performed with SPSS 16.0∗.  




Interrater reliability of the Premie-Neuro 
 Interrater reliability data were collected from a subset of 15 infants.  The 
average PMA at the time of interrater reliability assessment was 33.47 weeks (±1.73 
SD weeks).  All fifteen infants were administered the Neurologic and Movement 
subtests.  Mean total raw score for these two subtests was 67.20 (±3.99 SD points) for 
the hands-on examiner (E1) and 66.53 (±4.17 SD points) recorded by the observer 
(E2).  Interrater reliability was moderate for total raw score for two subtests 
(ICC=0.556, Table 2.3).  One infant was on a ventilator at the time of interrater 
reliability testing and was not administered the Responsiveness subtest.  Thus, 
xxxvi                                                 
∗ SPSS, 233 S. Wacker Drive, Chicago, Illinois, 60606 
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interrater reliability data for all 3 subtests were obtained from 14 infants.  Mean total 
raw score for all three subtests was 99.14 (±4.62 SD points) for the examiner and 
99.29 (±4.34 SD points) recorded by the observer.  Interrater reliability was fair for 
total raw score for all three subtests (ICC=0.391, table 2.3).  For Premie-Neuro 
classifications obtained for 15 infants by different examiners (E1 and E2) for the 
Neurologic and Movement subtests, κ=0.400 (p=0.121).  For classifications for the 
fourteen infants administered all three subtests, κ=0.143 (p=0.593, Table 2.3). 
 
Test-retest reliability of the Premie-Neuro 
 One-day test-retest reliability was collected from 30 infants (mean PMA at 
assessment 33.07 ± 2.26 SD weeks).  Four infants were not included in this analysis 
because of NICU discharge prior to administration of the second Premie-Neuro test.  
All 30 infants were administered the Neurologic and Movement subtests.  Mean total 
raw score for these two subtests was 68.40 (± 4.80 SD points) on day 1 and 66.20 (± 
5.57 SD points) on day 2.  One-day test-retest reliability for two subtests was 
moderate (ICC=0.493).  Four infants were on a ventilator at the time of short-term 
test-retest reliability testing, so 26 infants were administered all 3 subtests of the 
Premie-Neuro.  Mean total raw score for infants who were administered all three 
subtests was 100.54 (± 6.59 SD points) obtained on day 1 and 99.85 (±5.85 SD 
points) obtained on day 2.  Reliability of total raw score for all three subtests was 
moderate (ICC=0.592).  For the 30 infants who were administered the Neurologic and 
Movement subtests of the Premie-Neuro on consecutive days by E1, κ=0.429 
 
 38
(p=0.018).  For the 26 infants who were administered all 3 subtests, κ=0.133 
(p=0.484). Test-retest reliability data are summarized in Table 2.3. 
 
Stability of Premie-Neuro classifications 
 Eight infants were discharged from the NICU before the second week of 
testing.  For the 26 infants who were administered the Premie-Neuro on at least two 
consecutive weeks, the total number of Premie-Neuro assessments ranged from 2-10 
(mean=4.69 ± 2.24 SD assessments).  No infants tested in the abnormal classification 
throughout the course of the study.  Sixteen infants (61.54%) were classified as 
questionable for the majority of their assessments.  Eight infants (30.77%) were 
classified as normal for the majority of their assessments and 2 (7.69%) were 
classified as normal and questionable for an equal number of assessments.  Overall, 
infants tested in their most frequent classification an average of 79.52% of all 
assessments (Table 2.4). 
 
Comparison between high-risk and low-risk infants 
 All 34 subjects were administered at least one Premie-Neuro assessment in the 
NICU.  Using the NBRS, eleven infants were categorized as high risk (high risk 
group, HR) and the remaining twenty-three infants were categorized as low risk (low 
risk group, LR). As expected, scores were lower in the HR group versus the LR group 
at both the first and the discharge Premie-Neuro assessment (Table 2.5).  As shown in 
Table 2.6, there was a significant main effect of both post-menstrual age and risk 
 
 39
group on Premie-Neuro raw scores, and a significant interaction between risk group 
and post-menstrual age on Premie-Neuro raw scores.  Although scores for both 
groups declined over time, scores for infants in the HR group tended to decline at a 
much faster rate than infants in the LR group.  While scores for infants in the LR 
group tended to level off at approximately 32 weeks PMA and remained stable 
through term adjusted age, scores for infants in the HR group continued to fall as the 
infants approached term adjusted age (Figures 2.1 and 2.2).  There was not a 
significantly higher proportion of LR infants classified as normal versus HR infants at 
either the first (p=0.252) or discharge (p=0.053) Premie-Neuro assessment.  
 
Relationship between risk factors and Premie-Neuro raw scores and classifications 
 Oxygen-dependence at 36 weeks PMA and evidence of central nervous 
system injury were significant predictors of discharge Premie-Neuro raw scores 
(p=0.013 and 0.024, respectively).  Only oxygen-dependence at 36 weeks was 
predictive of the discharge Premie-Neuro classifications (p=0.038).  Gestational age 
at birth was not predictive of discharge Premie-Neuro scores or classifications and 
central nervous system injury was not predictive of discharge Premie-Neuro 




Although the majority of infants born preterm do well, they are at much 
greater risk for developmental disability and delay than their term counterparts (2, 3, 
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21, 31, 33, 34, 38, 41-44, 46, 50-52).  The risk of poor outcomes increases with 
neonatal medical complications such as bronchopulmonary dysplasia, central nervous 
system lesions, retinopathy of prematurity, and poor postnatal growth (21, 23, 24, 28, 
32, 44, 46, 47, 54, 55, 60, 61).  However, although these factors may predict 
outcomes in groups of infants, predicting individual outcomes remains difficult.  
There is mounting evidence that standardized developmental testing combined with 
informal clinical assessments and medical tests, such as MRI or cranial ultrasound, 
may be effective at identifying at-risk infants (57, 58).  However, there are few 
reliable and valid tools available for the clinician to assess the functional neurological 
status of the newborn in the NICU, particularly at less than 32 weeks PMA.  Our data 
show that the Premie-Neuro is a reliable and valid assessment tool for preterm 
infants, and may be used in combination with clinical examinations, general 
movement assessments, and/or neuroimaging to identify preterm infants most at-risk 
for developmental delay or disability.   
 Reliability values reported in this study for Premie-Neuro raw scores are 
slightly lower than those reported for many other assessment tools for preterm and 
newborn infants (65, 71, 72, 76, 89-92).  However—in our study—infants were tested 
as young as 29 weeks PMA and few other instruments have been validated on such a 
young group of infants.  Because preterm infants, particularly those at young post-
menstrual ages, are extremely variable in terms of their developmental trajectory, 
high reliability is difficult to achieve in this population.  In order to assess the true 
clinical reliability of the Premie-Neuro for the present study, the examiner and 
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observer did not participate in any formal training prior to beginning the study.  Each 
simply read the instruction manual and watched the training video, as recommended 
by the authors of the Premie-Neuro.  After the completion of the study, both the 
examiner and the observer reported that the instructions in the administration manual 
were often unclear or lacking sufficient detail.  A more structured approach to 
training and a more detailed administration manual may enhance the interrater 
reliability of the Premie-Neuro.  It is worth noting that our data for both test-retest 
and interrater reliability showed that mean total score varied little by day or between 
observer and examiner, respectively.  In some cases, mean total raw score differed by 
less than one point.  This shows that reliability of the Premie-Neuro may be more 
clinically significant than is reflected statistically.  Although interrater or test-retest 
reliability of Premie-Neuro raw score is not substantial or near perfect according to 
Landis and Koch criteria (88), it is fair to moderate and therefore acceptable for 
clinical use in this highly-variable  preterm infant population. 
 Interrater and one-day test-retest reliabilities of Premie-Neuro classifications 
are not as strong as the reliabilities of Premie-Neuro raw score.  This is particularly 
true for classifications based on all 3 subtests versus classifications based upon only 2 
subtests.  Based on our results, we would suggest that the clinician use caution when 
interpreting Premie-Neuro classifications obtained over a short period of time (1-3 
days).  It may be more appropriate to interpret classifications over a longer period of 
time (one week or longer), as our data showed good, clinically significant stability of 
Premie-Neuro classifications over consecutive weeks. 
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 To assess the construct validity of the Premie-Neuro, two methods were used.  
First, we assessed whether the Premie-Neuro could discriminate between two groups 
of infants known to differ in terms of risk for developmental disability and/or delay.  
As expected, HR infants had worse Premie-Neuro scores than LR infants, and the 
difference in Premie-Neuro raw scores between groups increased as infants 
approached term adjusted age.  This is consistent with previous research that showed 
that, using the Test of Infant Motor Performance (TIMP),  low-risk preterm infants 
tended to catch up with their full-term counterparts as they approached term and post-
term adjusted ages, while high-risk preterm infants fell further behind over time (74, 
92).  Although the Premie-Neuro was excellent in discriminating between HR and LR 
infants in terms of raw score, it did not discriminate between HR and LR infants in 
terms of classifications.   
Construct validity of the Premie-Neuro was also assessed by determining 
whether oxygen-dependence at 36 weeks PMA, central nervous system injury, and 
GA age at birth—all factors that have been shown to be predictive of later 
neurodevelopmental disability and/or delay—were predictive of Premie-Neuro scores 
and classifications.  CNS injury and oxygen-dependence at 36 weeks PMA were 
predictors of Premie-Neuro total raw scores and only oxygen-dependence at 36 weeks 
PMA predicted Premie-Neuro classifications.  This is consistent with literature 
showing that infants with abnormal cranial ultrasound findings and/or a significant 
history of respiratory illness and insufficiency tend to have worse long-term outcomes 
than healthy preterm babies (23, 28, 46, 47, 52, 54, 55, 60, 61).  We were surprised to 
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find that, in the present study, central nervous system injury was not predictive of 
Premie-Neuro classifications.  However, only six babies in the study had documented 
CNS injury, and the lack of significance may be due to the small sample size of this 
group.  Gestational age at birth was not an independent predictor of Premie-Neuro 
scores or classifications, which is in agreement with other studies that have shown 
that—although children born at younger GA are at greater risk for poor 
neurodevelopmental outcomes—those outcomes are not as strongly tied to 
immaturity itself as they are to poor postnatal growth and medical complications that 
are often associated with extreme prematurity (2, 24, 32, 62). 
 Although Premie-Neuro raw scores were reliable and valid to a level that 
confirmed clinical relevance, reliability and validity of Premie-Neuro classifications 
were inconsistent and generally poor.  We believe there are two possible explanations 
for this discrepancy.  First, this study included a relatively small sample of preterm 
infants in the HR group and with CNS injury.  It is possible that, due to these small 
sample sizes, our nonparametric statistical tests did not have sufficient power to 
detect differences.  Another explanation—and one we believe is more likely—is that 
the currently recommended raw score cut-points for normal, questionable, and 
abnormal Premie-Neuro classifications may need to be modified.  In the present 
study, a total of 118 full Premie-Neuro tests were administered on 34 infants.  Overall 
mean Premie-Neuro score for these tests was 95.8.  The mean Premie-Neuro total raw 
score for LR infants was 100.1, while the mean Premie-Neuro score for HR infants 
was 90.  The current cut-points for Premie-Neuro classifications are abnormal for a 
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score of 69 or less, questionable for a score of 70-100, and normal for a score greater 
than 100.  Our data show that low-risk, healthy preterm babies tended to have Premie-
Neuro scores on the borderline of the current questionable and normal categories, 
while sicker high-risk babies tended to score in the middle of the questionable 
category.  Thus, many low-risk, otherwise healthy babies with raw scores just under 
100 were classified as neurologically questionable during the course of the study.  No 
infants in this study were classified as abnormal on any assessment using the 




 There is a need for a clinical neurological assessment tool that may be used in 
the NICU to identify infants at-risk for developmental delay.  The Premie-Neuro is a 
quick, non-invasive assessment that may be easily administered by an experienced 
clinician.  This study shows that Premie-Neuro scores meet reliability and validity 
criteria expected in this fragile population and thus may be used as an adjunct to 
clinical assessment to identify at-risk infants.  However, Premie-Neuro classifications 
do not have adequate reliability and validity and should be interpreted with caution.  
Modification of Premie-Neuro cut-points may enhance its reliability, validity, and 
clinical utility as an early screening for developmental disability and delay.  Future 
research is needed to further determine the psychometric properties of the Premie-
Neuro and to determine if modification of classification cut-points does, indeed, 




















Table 2.1. Premie-Neuro Test Items.  The Responsiveness subtest may only be 
administered to infants ≥ 28 weeks PMA and who do not require mechanical 
ventilation.  The Neurologic and Movement subtests may be administered to all 
preterm infants.  
Subtest       Items 
Neurologic 1. Arm Recoil 
2. Arm Traction 
3. Palmar Grasp 
4. Plantar Grasp 
5. Scarf Sign 
6. Popliteal Angle 
7. Heel to Ear 
8. Movement Type 
 
Movement 1. Tremors 
2. Thrashing 
3. Facial Grimace 
4. Startle 
5. Yawn 
6. Color Change 
7. Arm Movements  
8. Leg Movements 
 
Responsiveness 1. Arm Flexion 
2. Head Lag 
3. Held Sit 
4. Posterior Neck 
5. Anterior Neck 
6. Alert 





Table 2.2. Description of study participants.  Data are mean (standard 
deviation).  GA=Gestation Age; BW=Birth Weight. 
 Sex GA at  
birth, 
weeks 
BW, grams Birth order Race/ 
ethnicity  
























































Table 2.3. Intraclass correlation coefficients for interrater and test-retest 
reliabilities of Premie-Neuro raw score, and Kappa agreements for interrater 
and test-retest reliabilities of Premie-Neuro classifications.  Interrater and test-
retest reliabilities of Premie-Neuro raw scores were fair to moderate for two and 
three subtests.  Interrater and test-retest reliabilities of the Premie-Neuro 
classifications was fair to moderate for two subtests, but only slight for all three 
subtests. 
*n=14, One infant was on a ventilator at the time of interrater reliability testing 
and was only administered 2 subtests. 
**n=26, Four infants were on a ventilator at the time of test-retest reliability 












   













Premie-Neuro test week 







1 Q N N Q Q Q Q    Q 71.43 
2 N Q N N N Q N    N 71.43 
3 N N         N 100 
4 Q N Q        Q 66.67 
5 Q N N        N 66.67 
6 N N Q Q Q Q     Q 66.67 
7 Q N Q Q Q Q     Q 83.33 
8 Q Q         Q 100 
9 N N N N Q N     N 83.33 
10 N N N Q Q Q     N/Q 50 
11 N N         N 100 
12 Q Q         Q 100 
15 N Q N N Q Q Q    Q 57.14 
16 Q Q Q N Q Q Q Q   Q 87.5 
18 Q N N Q Q Q Q Q Q Q Q 80 
20 N N Q        N 66.67 
24 N N N N Q Q     N 66.67 
25 Q Q N        Q 66.67 
26 N Q         N/Q 50 
28 N N N        N 100 
29 Q Q Q Q       Q 100 
30 Q Q Q Q Q Q Q    Q 100 
31 Q Q Q        Q 100 
32 N  Q Q Q       Q 75 
33 Q N Q Q Q Q     Q 83.33 
34 N Q Q Q       Q 75 
            Mean= 79.52 





 First PN score Discharge PN Score 
High Risk Group 
(n=11) 
2 subtests:  
64.36 (7.74) 
 








Low Risk Group 
(n=23) 
2 subtests (n=15)**: 
71.07 (4.27) 
 










2 subtests (n=26)**: 
68.23 (6.75) 
 







Table 2.5. Premie-Neuro scores for high-risk and low-risk infants.  Data are 
mean (standard deviation).  PN=Premie-Neuro. 
* Four infants were on ventilators at first PN assessment and were only 
administered 2 subtests 
**Eight infants were only administered one weekly PN assessment.  In that case, 






Neurologic and Movement  
subtests only 
Neurologic Movement, and  
Responsiveness subtests 
PMA p=0.001* p=0.000* 
Risk Group p=0.000* p=0.000* 
PMA x Risk Group p=0.004* p=0.010* 
Table 2.6. Two Factor (Risk Group, PMA) Repeated Measures Analysis of 
Variance (n=34).  Premie-Neuro total raw score was the dependent variable.  
There were significant main effects of both PMA and Risk Group, and a 






 Dependent variable:  
discharge PN total raw score 
Dependent variable:  
discharge PN classification 
Predictors in the 
model 
BPD (p=0.013)* 
CNS lesion (p=0.024)* 
BPD (p=.038)* 
CNS lesion (p=0.999)  
Table 2.7. Linear and logistic regression analyses with stepwise elimination.  
BPD and CNS lesion were significant predictors of discharge PN raw score, only 
BPD was a significant predictor of discharge PN classification.  Gestational age 
at birth was not included in either regression model due to lack of significance.  
BPD=Bronchopulmonary Dysplasia defined as oxygen dependence at 36 weeks 















29 2 1 3 
30 2 1 3 
31 6 5 11 
32 5 6 11 
33 5 6 11 
34 7 8 15 
35 8 16 24 
36 9 14 23 
37 6 11 17 
Total 50 68 118 
Table 2.8. Number of full Premie-Neuro assessments (3 subtests) administered at 





2.7 Figure Legend 
Figure 2.1. Weekly Premie-Neuro scores for HR and LR infants.  After 32 weeks 
PMA, mean scores for LR infants tended to remain stable while scores for the HR 
infants declined as they approached term adjusted age.  LR=Low Risk Group; 
HR=High Risk Group; PMA=Post-menstrual Age. 
 
Figure 2.2. Weekly Premie-Neuro scores for HR and LR infants.  Data collected at 29 
and 30 weeks post-menstrual age were removed as there was only one data point in 
the LR group and two data points in the HR group for each of those weeks.  There 





















































































 Predicting long-term outcomes for the preterm infant is a complex and 
difficult task, and there are few standardized assessment tools for this population with 
established predictive validity.  In the present study, we set out to determine if 
performance on the Premie-Neuro—a standardized neurological assessment for 
preterm infants 23 through 37 weeks post-menstrual age (PMA)—could predict 
neurodevelopmental outcomes at term and 3 months adjusted age.  Thirty-four 
preterm infants were administered the Premie-Neuro weekly in the NICU through 37 
weeks post-menstrual age (PMA) or discharge, whichever occurred first.  At 38-42 
weeks PMA, infants were assessed using the NeoNeuro.  At 3 months adjusted age, 
infants were assessed using the Infanib and AIMS.  Based on their performance, 
infants were classified as normal or not normal on all assessments based on 
recommended cut-points.  We found that Premie-Neuro raw scores had fair to 
moderate ability to predict outcomes at term and 3 months adjusted age, and that the 
predictive value of Premie-Neuro scores improved as infants approached term 
adjusted age.  Premie-Neuro classifications were generally not predictive of 
NeoNeuro classifications at term or Infanib and AIMS classifications at 3 months 
adjusted age.  These data suggest that Premie-Neuro raw scores may be used by the 
clinician to identify infants at-risk for neurodevelopmental delays.  However, Premie-
Neuro classifications should be interpreted cautiously.  Future research is needed to 
assess the role of growth and development on Premie-Neuro score and to determine if 
modification of raw score cut-points used to classify assessments as normal, 
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 Prematurity—defined as birth prior to 37 weeks gestational age—is one of the 
leading causes of infant death and neurodevelopmental disabilities such as cerebral 
palsy, developmental coordination disorder, learning disabilities, and low IQ (2, 3, 
21, 43, 93, 94).  Although improvements in medical care since the mid- to late-1990s 
have led to improved neurodevelopmental outcomes in preterm infants (6, 7), the rate 
of preterm birth in the United States continues to rise each year (1) and there are 
disproportionate numbers of preterm children who require specialized care, early 
intervention services, and special education throughout childhood.  For example, in 
Massachusetts, Clements and colleagues reported that the cost of early intervention 
services per preterm child was over 2-7 times the amount spent per term child.  The 
largest discrepancy in dollars spent was for physical and occupational therapy, 
reflecting a focus on motor delay and disability in this population (64).  However, 
research indicates that early intervention does not improve motor outcomes for 
preterm infants who receive such services simply because they are preterm (9, 10).  
Rather, early intervention is only proven to be effective for a subset of preterm infants 
who are identified as at-risk using standardized neurological assessment tools (12, 
13).  In a time when rates of preterm birth are rising and state and federal budgets are 
shrinking, it is increasingly important to maximize efficiency and cost-effectiveness 
of early intervention services for preterm children.  Early prediction of 
neurodevelopmental delay has never been more important. 
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Prediction of neurodevelopmental outcomes in preterm infants is complicated, 
and it is particularly difficult to predict individual outcomes.   Neuroimaging—often 
cranial ultrasound or, less frequently, magnetic resonance imaging (MRI)—is often 
used to identify children with brain lesions as “high risk.”  However, children with 
documented brain lesions often have no functional neurological deficits, while 
children without evidence of early brain injury sometimes go on to have significant 
disability (24).  Research suggests that the prediction of neurological dysfunction is 
best when perinatal risk factors, including results of neuroimaging, are considered 
along with the results of clinical neurological assessments (57, 58). Unfortunately, 
there are few standardized assessment tools for use in the NICU with established 
predictive validity, so the clinician must often rely on his or her own clinical expertise 
to predict outcomes.  Clinicians may struggle with the choice of whether to refer 
groups of preterm infants for early intervention services based on risk factors—
resulting in a potential over-utilization of services—versus possibly under-utilizing 
services while waiting to make those referrals until evidence of delay or disability is 
undeniable.  A predictive standardized neonatal neurological assessment tool would 
aid the clinician in making prognoses and appropriately referring infants—or not—for 
developmental follow-up and/or early intervention services. 
  The Premie-Neuro is a standardized neurological assessment tool for infants 
23 through 37 weeks post-menstrual age (PMA).  It contains items that measure 
active and passive tone, reflexes, and behavioral signs of stress.  The Premie-Neuro 
consists of 8 items in each of 3 subtests—Neurological, Movement, and 
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Responsiveness—for a total of 24 items (78).  It requires little training and can be 
easily administered in 5-10 minutes by the experienced clinician.  Internal 
consistency of the Premie-Neuro is good (14).  In Chapter 2, we reported results from 
our work showing that Premie-Neuro raw scores had fair to moderate interrater and 
test-retest reliability.  Construct validity was also strong as the Premie-Neuro 
distinguished between groups of infants known to differ in terms of risk for 
developmental delay and disability.  Although preliminary work has shown that the 
Premie-Neuro may have acceptable predictive validity through 6-8 months adjusted 
age (79), this has never been formally studied.  Thus, the purpose of the present study 
was to determine the predictive validity of the Premie-Neuro.  Specifically, we set out 
to determine if performance on the Premie-Neuro in the NICU could predict 
performance on the NeoNeuro, a neurological assessment for young infants (95), at 
38-42 weeks PMA.  We also examined the relationship between NICU Premie-Neuro 
performance and performance on the Infanib (90), a neurological test for older 
infants, and Alberta Infant Motor Scale (96), a test of motor development for older 





 Thirty-four preterm infants were tested with the Premie-Neuro at least once in 
the NICU and participated in follow-up testing at term and/or 3 months adjusted age.  
A description of the infants who participated in this study is provided in table 3.1.  
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Infants were included in the study if they were born prior to 37 weeks gestation, were 
no more than 37 weeks PMA at the time of the first Premie-Neuro assessment, and if 
their physician agreed that they were medically stable enough to undergo hands-on 
clinical assessment.  Infants were excluded from the study if they had a known 
genetic disorder or major congenital anomaly.  In accordance with the Human 
Subjects Committee, each participant’s parent or guardian signed an institutionally 
approved parental consent form.   
 
NICU testing procedure 
 Premie-Neuro testing began as soon as possible after the infant’s physician 
determined each participant was sufficiently medically stable to undergo hands-on 
assessment.  All Premie-Neuro testing was conducted by a physical therapist in the 
infant’s crib or isolette, and all assessments were completed within the hour prior to 
each infant’s scheduled feeding time when possible.  Prior to each test, the infant’s 
physician and/or nurse were contacted to ensure there were no medical 
complications—such as an acute illness or infection—that would limit the babies’ 
ability to participate in the assessments.  Physiological signs of stress—such as heart 
rate and oxygen saturation—were monitored throughout each testing session, and 
testing was discontinued and/or canceled and rescheduled if the infant showed 
significant signs of stress.  The Premie-Neuro was administered approximately 
weekly (once every 5-9 days) through 37 weeks PMA or discharge, whichever 
occurred first.  
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 In accordance with administration guidelines, infants who were 28 weeks 
PMA or younger or who were on a ventilator were only administered the Neurologic 
and Movement subtests of the Premie-Neuro, a total of 16 items.  Infants older than 
28 weeks PMA and not on a ventilator were administered all 24 items in the 3 
subtests.  Each item was assigned a score of one, three, or five based on the infant’s 
gestational age and performance on the item. Item scores were tallied and each 
infant’s assessment was classified as neurologically normal, questionable, or 
abnormal based on raw score cut-points provided in The Premie-Neuro Examination 
Instruction Manual (78).   
 
Follow-up testing at term adjusted age  
 At 38-42 weeks PMA, the NeoNeuro was administered by a physical 
therapist.  If the infant remained in the NICU at term adjusted age, testing was 
conducted in the NICU at bedside.  If the infant was discharged from the NICU, 
testing was conducted in the home or the NICU follow-up clinic depending on parent 
preference.   
 The NeoNeuro consists of 32 items assessing tone and movement, reflexes, 
and neurobehavior in infants from 38 weeks PMA to 16 weeks adjusted age.  Each 
item is assigned a score of 1, 3, or 5 based upon the infant’s adjusted age and 
performance on the item.  Individual item scores are tallied for a total score, and the 
assessment is classified as normal, mildly abnormal, moderately abnormal, or 
severely abnormal based on raw score cut-points recommended by the NeoNeuro 
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authors (95).  Reliability and validity of the NeoNeuro has been tested.  Internal 
consistency is 0.80 and test-retest reliability over one week is 0.73.  Construct validity 
of the NeoNeuro has been demonstrated by its ability to distinguish between infants 
who are neurologically normal, suspect, or abnormal (65, 95).  We chose to assess 
infants at term adjusted age using the NeoNeuro because the items it includes—
assessing active and passive tone, reflexes, and neurobehavior—measure a similar 
construct as the Premie-Neuro. 
 
Follow-up testing at 3 months adjusted age 
 At approximately 3 months adjusted age, infants were assessed by a physical 
therapist using two tools:  the Alberta Infant Motor Scale (AIMS) and the Infanib.  
No infants remained in the NICU at 3 months adjusted age, so all testing was 
conducted in the infant’s home or the NICU follow-up clinic according to caregiver 
preference.  
 The Infanib is a criterion-referenced neuromotor assessment that may be 
administered to infants age birth to 18 months.  The Infanib consists of 20 items, 15 
of which are appropriate to administer to a child who is less than 4 months adjusted 
age.  All 15 of those items were administered to each participant, and each infant was 
given a score of 1, 3, or 5 based on performance on the item.  Item scores were tallied 
for a total score, and each assessment was categorized as normal, transient, or 
abnormal based on  raw score cut-points provided in the administration manual (90).  
Previous studies have established the reliability and validity of the Infanib for use in 
 
 65
research and clinical practice, determining that the interrater reliability was 0.97 and 
test-retest reliability was 0.95 (90).  We chose to administer the Infanib at 3 months 
adjusted age because—like the Premie-Neuro and NeoNeuro—the Infanib assesses 
tone and posture.  Thus, we believe the Infanib measures a similar construct as the 
Premie-Neuro and NeoNeuro. 
 The AIMS is a norm-referenced assessment that can be administered on 
infants 0-18 months (96). The AIMS contains four subscales:  prone, supine, sit, and 
stand. The AIMS was administered to each participant in its entirety by observing 
motor performance in each of these positions.  Total raw score was tallied and a 
percentile rank was calculated based on the infant’s adjusted age.  Each infant’s 
assessment was classified as normal if gross motor skills fell at or above the 10th 
percentile rank and  abnormal if motor skills fell below the 10th percentile rank (97).  
The psychometric properties of the AIMS have been well-documented.  Using the 
10th percentile as a cut-point, the AIMS had a specificity of 81.7% and a sensitivity of 
77.3% when administered on 4-month-old infants.  Interrater reliability of the AIMS 
was >0.95 and test-retest reliability ranged from 0.86-0.99.  Concurrent validity of the 
AIMS with other established motor evaluations ranged from 0.84 to 0.99 (68, 96).  
The AIMS differs from the Premie-Neuro, NeoNeuro, and Infanib in that it is a 
measure of gross motor development and does not focus on specific neurological 
signs such as primitive reflexes and muscle tone.  In the present study, we chose to 
administer the AIMS at 3 months adjusted age to determine if the predictive abilities 
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In order to assess the predictive validity of the Premie-Neuro raw scores, 
Pearson correlations were calculated to determine the relationship between Premie-
Neuro scores in the NICU and NeoNeuro score at term and Infanib and AIMS scores 
at 3 months adjusted age.  In the present study, we chose to test correlations 
associated with raw scores from both the first Premie-Neuro test and the final Premie-
Neuro test administered before discharge from the NICU.  During the course of our 
study, no Premie-Neuro assessment was classified as abnormal.  Thus, to examine 
predictive validity of Premie-Neuro classifications, we did not change the author 
recommendations for classifying an assessment as “normal,” but we did collapse the 
author-recommended questionable and abnormal classifications into one “not normal” 
classification.  Similarly, we collapsed author-recommended NeoNeuro and Infanib 
classifications into “normal” and “not normal.”  Recommended AIMS classifications 
were binary, so no modification of classifications was necessary for data analysis.  
We compared Premie-Neuro classifications in the NICU to NeoNeuro classifications 
at term and Infanib and AIMS classifications at 3 months adjusted age using Fisher’s 
exact test.  Again, we chose to look at only classifications obtained at the first and 
discharge Premie-Neuro assessments.   
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Eight infants were only administered one Premie-Neuro assessment while in 
the NICU due to discharge before a second test could be administered.  These scores 
and classifications were included in analyses for the discharge Premie-Neuro 
assessment.  Four infants were on a ventilator at the time of the first Premie-Neuro 
assessment.  Per testing guidelines, those infants were administered only the 
Neurologic and Movement subtests at their first assessment.  Thus, of the 34 infants 
included in our sample, scores for all 3 subtests were recorded and analyzed for 22 
infants and scores for 2 subtests were obtained for 26 infants at the first Premie-Neuro 
assessment.  All infants were off the ventilator at the time of the discharge Premie-
Neuro assessment, so scores for 2 and 3 subtests were recorded and analyzed for all 
34 infants for the discharge Premie-Neuro assessment.   
Of the original 34 subjects, one infant’s family could not be contacted for term 
follow-up.  Thus, 33 infants were included in analyses for predictive validity at term 
adjusted age.  At 3 months adjusted age, five infants’ families could not be reached, 
three infants’ families had relocated, and one infant was deceased.  Thus, 25 infants 
were included in analyses for predictive validity at 3 months adjusted age.  Analyses 
were performed with SPSS 16.0∗.  Significance was set at p<0.05.  All data are 
reported as mean ± standard deviation. 
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At the first Premie-Neuro assessment, infants ranged in age from 29 to 36 
weeks PMA, with a mean PMA at first Premie-Neuro assessment of 32.35 weeks 
(±2.48 weeks).  At the discharge Premie-Neuro assessment, infants ranged in age 
from 32 to 37 weeks PMA (mean PMA 36.0 ±1.18 weeks).  Mean scores for 2 and 3 
subtests at the first and discharge Premie-Neuro assessments are summarized in Table 
3.2. 
 
Predictive validity of the Premie-Neuro at term adjusted age 
 Pearson correlations between NeoNeuro scores at term and Premie-Neuro raw 
scores at the first and discharge Premie-Neuro assessments for infants who were 
administered both two and three subtests ranged from 0.489-0.700.  All correlations 
were statistically significant (Table 3.3, Figure 3.1.a).  
 There was no significant association between the first Premie-Neuro 
classifications and NeoNeuro classifications at term (p=0.411).  However, there was a 
significant association between the discharge Premie-Neuro classifications and 
NeoNeuro classifications at term (p=0.003, Table 3.4).  The first Premie-Neuro 
classifications were 59% sensitive and 63% specific for predicting NeoNeuro 
classifications at term.  Sensitivity and specificity of the discharge Premie-Neuro 
classifications for predicting NeoNeuro classifications at term was 85% and 69%, 




Predictive validity of the Premie-Neuro at 3 months adjusted age 
 Table 3.3 and Figures 3.1.b and 3.1.c describe Pearson correlations between 
Premie-Neuro raw scores and Infanib and AIMS raw scores at 3 months adjusted age.  
All Pearson correlations between the discharge Premie-Neuro scores for both 2 and 3 
subtests and Infanib and AIMS scores at three months adjusted age were statistically 
significant, ranging from 0.446-0.573.  The first Premie-Neuro scores for infants 
administered 2 or 3 subtests were not significantly correlated with Infanib or AIMS 
scores at 3 months adjusted age.   
 While there was a significant correlation between the raw scores of the 
discharge Premie-Neuro assessments and the Infanib and AIMS raw scores at 3 
months adjusted age, the ability of the Premie-Neuro to predict neurologically 
“normal” versus “not normal” classifications of babies at 3 months adjusted age was 
not good.  There was not a statistically significant relationship between the first or the 
discharge Premie-Neuro classifications and Infanib or AIMS classifications at 3 
months adjusted age (Table 3.3).  The first Premie-Neuro classifications were 75% 
sensitive and 53% specific in predicting AIMS classifications and 50% sensitive and 
40% specific in predicting Infanib classifications at 3 months adjusted age.  
Sensitivity of the discharge Premie-Neuro classifications was 100% and specificity 
was 57% for predicting AIMS classifications.  Sensitivity and specificity of the 
discharge Premie-Neuro classifications in predicting Infanib classifications were 61% 






 Despite great improvements in rates of major medical complications in 
preterm infants, there is no question that these babies are at greater risk for 
developmental disability and delay than their term counterparts.  Research indicates 
that early intervention services may improve neuromotor outcomes, but only in a 
subset of preterm babies who are identified as at-risk (9, 10, 12, 13).  Thus, early 
detection of at-risk infants is critically important so that clinicians may make 
appropriate recommendations for referring or not referring preterm babies for 
specialized early intervention services such as physical or occupational therapy.  
There is growing consensus that standardized neurological testing should be 
considered in combination with clinical assessment, medical risk factors, and medical 
testing to improve the prediction of poor outcomes in preterm babies (57, 58).  In the 
present study, we set out to determine whether one such standardized test—the 
Premie-Neuro—had acceptable predictive validity to be used to identify at-risk 
infants in the NICU.  Our findings suggested that Premie-Neuro raw scores were 
predictive of performance on the NeoNeuro at term and the Infanib and AIMS at 3 
months adjusted age.  However, Premie-Neuro classifications did not seem to predict 
the classifications of other standardized tests at term and 3 months adjusted age. 
 As expected, the discharge Premie-Neuro raw score was a stronger predictor 
of outcomes at both term and 3 months adjusted age than the first Premie-Neuro 
score.  This may be due in part to the fact that neurological development is often 
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confounded with sickness at early preterm ages.  Although sicker babies with more 
medical complications do tend to have worse neurological outcomes, this is not 
necessarily a causal relationship and poor performance by a very sick preterm infant 
may not be reflective of his or her true developmental capabilities.  By the discharge 
Premie-Neuro assessment, all infants in the present study were off of a ventilator and 
were sufficiently medically stable to be near discharge from the NICU.  As such, the 
discharge Premie-Neuro assessment was probably much more reflective of true infant 
neurological function than the first Premie-Neuro assessment.  Furthermore, the 
discharge Premie-Neuro assessment was temporally closer to term and 3-month 
assessments, which likely resulted in increased correlations between the discharge 
Premie-Neuro scores and scores at follow-up testing.   During the course of this 
study, Premie-Neuro raw scores seemed to have a floor effect.  In other words, at very 
young preterm ages, some Premie-Neuro items—particularly those included in the 
Responsiveness subtest—did not seem to be sensitive enough to detect 
neurodevelopmental delays and differentiate between normal and abnormal 
responses.  For example, an item in the Responsiveness subtest examines whether the 
baby can hold his head up in supported sitting.  The inability to hold the head upright 
in this position is considered a normal response through 33 week PMA.  Thus, for 
many babies who would later struggle with head control and score abnormally on this 
item, the early response of the head remaining forward or backward was considered 
normal and difficulty with this item was often not detected until the baby could not 
hold his head upright at 34-37 weeks PMA.  Because our data show quite clearly that 
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the predictive value of Premie-Neuro score improves with age, further research is 
needed to determine what other factors (such as respiratory status, illness, growth) 
may affect the reliability and validity of the Premie-Neuro scores, particularly at early 
preterm ages.   Furthermore, it would be beneficial to determine if there is a certain 
age or stage of development when the Premie-Neuro scores become significantly 
more reliable or valid, as this may represent a window of opportunity when Premie-
Neuro testing and early detection may be most valuable. 
 According to Portney and Watkins (98), in the behavioral sciences, lower 
correlations—those that may not necessarily be statistically significant—may be used 
as “evidence of functional useful relationships.”  Although they caution that rigid cut-
points should not be used, they state that correlations between 0.25-0.50 may show 
fair relationships and correlations 0.51-0.75 may show moderate relationships.  Using 
these criteria, correlations in this study revealed fair to moderate, statistically 
significant relationships between both the first and discharge Premie-Neuro raw 
scores in the NICU and NeoNeuro raw scores at term.  The discharge Premie-Neuro 
raw scores also had fair to moderate, statistically significant relationships with Infanib 
and AIMS scores at 3 months adjusted age.  According to the Portney and Watkins 
criteria, the first Premie-Neuro scores had a fair relationship with Infanib scores at 3 
months adjusted age, although this was not a statistically significant relationship.  The 
first Premie-Neuro scores had little to no relationship with AIMS scores at 3 months 
adjusted age. This discrepancy may exist because the Premie-Neuro, NeoNeuro, and 
Infanib assess a similar construct (neurological function) while the AIMS assesses a 
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somewhat different construct (motor development).  Another possible explanation is 
that neurological development at early preterm ages—as measured by the Premie-
Neuro—simply may not be as reflective of future motor development as neurological 
function at preterm ages closer to term. 
 Although the predictive validity of the Premie-Neuro raw score was generally 
quite good, Premie-Neuro classifications had poor predictive value overall.  The 
discharge Premie-Neuro classifications were only predictive of NeoNeuro 
classifications at term and was not predictive of classifications at 3 months adjusted 
age.  The first Premie-Neuro classifications were not predictive of classifications at 
term or 3 months adjusted age.    One limitation of the present study was the 
relatively small, homogenous sample of infants.  As stated previously, during the 
course of our study, no infant tested in the “abnormal” classification on any Premie-
Neuro assessment.  Because of this, we chose to collapse classifications of all 
assessments into two categories—normal and not normal—for data analyses.  Perhaps 
a different method of collapsing categories, such as collapsing normal and 
questionable Premie-Neuro classifications into one group and abnormal 
classifications into a second group—would have enhanced predictive validity of 
Premie-Neuro classifications.  Unfortunately, we were unable to do this for our 
sample because of the lack of infants who tested as abnormal in the study.  A larger, 
more heterogeneous sample of infants may have allowed analyses that would have 
been able to capture the subtle variations between infants in different classifications.  
However, even in a large sample, we would still expect very few babies to test in the 
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abnormal range and many of those babies scoring in the abnormal range of the 
Premie-Neuro may be too fragile to test at early preterm ages.  Thus, the sample 
tested here appears to represent a typical group of babies that would be available to 
the clinician for assessment. 
 Another possible explanation for the poor predictive validity of Premie-Neuro 
classifications—despite good predictive validity of the Premie-Neuro raw scores—is 
that the raw score cut-points set by the Premie-Neuro authors during the construction 
of the test may need to be adjusted.  Future studies are needed to determine if 
adjusting the raw score cut-points and/or modifying the classification system would 
enhance the predictive validity of the Premie-Neuro classifications and improve the 




 Prediction of outcomes in preterm infants is difficult, even for an experienced 
clinician, and there are currently few standardized tools available for clinicians to 
identify at-risk infants and differentiate between infants with neurodevelopmental 
delays that are mild or severe, transient or persistent.  In the current study, we found 
that the Premie-Neuro raw scores had fair to moderate predictive validity.  Although 
the Premie-Neuro raw scores obtained early in the infants’ NICU stays had some 
predictive value, the discharge Premie-Neuro scores were the strongest predictors of 
outcomes at term and 3 months adjusted age.  The predictive value of the Premie-
Neuro classifications at term and 3 months adjusted age was generally poor.  
 
 75
Clinicians should interpret Premie-Neuro classifications with caution.  Our data 
suggest that Premie-Neuro raw scores, particularly at older preterm ages, are 
predictive of outcomes at term and 3 months adjusted age, and may be used to 
identify at-risk infants in the NICU.  Modification of Premie-Neuro raw score cut-
points for classifying assessments as normal, questionable, or abnormal may enhance 




Table 3.1. Description of study participants.  Data are mean (standard 
deviation).  GA=Gestational Age; BW=Birth Weight.

























 First PN score (n=26*) Discharge PN Score (n=34) 
2 subtests  68.23 (6.75) 66.65 (8.00) 
 
3 subtests 100.55 (6.99)** 95.24 (10.75) 
Table 3.2. Summary of raw scores at the first and discharge Premie-Neuro 
assessments.  Data are mean (standard deviation).  Raw score cut-points for 
classifications based on 3 subtests: ≥100 normal, 70-99 questionable, <70 
abnormal.  Raw score cut-points for classifications based on 2 subtests: ≥70 
normal, 50-69 questionable, <50 abnormal (78).  PN=Premie-Neuro. 
*Eight infants were only administered one weekly PN assessment.  In that case, 
the assessment was entered as discharge PN. 
* *Four infants were on ventilators at first PN assessment and were only 











First Premie-Neuro ** 
     2 subtests  











Discharge Premie-Neuro  
     2 subtests  










Table 3.3. Pearson correlation coefficients for first and discharge Premie-Neuro 
scores for two and three subtests and NeoNeuro scores at term and Infanib and 
AIMS scores at three months adjusted age.  The discharge Premie-Neuro raw 
scores were significantly correlated with raw scores obtained using the 
NeoNeuro at term and the Infanib and AIMS at 3 months adjusted age.  The 
first Premie-Neuro raw scores were significantly correlated with NeoNeuro raw 
scores at term, but not with Infanib and AIMS raw scores at 3 months adjusted 
age.  AIMS=Alberta Infant Motor Scale. 
*p<0.05 
** Eight infants were only administered one weekly PN assessment.  In that case, 
the assessment was entered as discharge PN (n=26). 
#
Four infants were on ventilators at first PN assessment and were only 




 First PN  Discharge PN   
NeoNeuro p=0.411 p=0.003* 
Infanib p=1.000 p=0.202 
AIMS p=0.582 p=0.096 
Table 3.4. Fisher’s exact test for the first and discharge Premie-Neuro 
classifications and NeoNeuro classifications at term and Infanib and AIMS 
classifications at 3 months adjusted age.  The only statistically significant 
relationship was between the discharge Premie-Neuro classifications and 










AIMS (3 months AA) 
 
100% 57% 
Infanib (3 months AA) 61% 71% 
Table 3.5. Sensitivity and specificity of the discharge Premie-Neuro 
classifications for predicting NeoNeuro classifications at term or Infanib and 
AIMS classifications at 3 months adjusted age.  PN=Premie-Neuro, 
AIMS=Alberta Infant Motor Scale 
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3.7 Figure Legend 
 
Figure 3.1. Scatterplot showing Pearson correlations between the discharge Premie-
Neuro raw scores and (a) NeoNeuro raw scores at term, (b) Infanib raw scores, and 
(c) AIMS raw scores at 3 months adjusted age.  All correlations were significant at 























Modifying raw score cut-points improves reliability, validity, and predictive 





 The Premie-Neuro is a new test of neurological development for preterm 
infants.  In Chapters 2 and 3, we showed that Premie-Neuro raw scores had 
acceptable reliability, could differentiate between groups of infants known to differ in 
terms of risk for delay and disability, and were predictive of outcomes at term and 3 
months adjusted age.  However, Premie-Neuro classifications using raw score cut-
points recommended in The Premie-Neuro Examination Instruction Manual (78) to 
classify assessments as normal (raw scores ≥ 100) and not normal (questionable and 
abnormal, raw scores <100) were not reliable and valid.  In the present study, we 
examined whether modifying the raw score cut-points for classifying Premie-Neuro 
assessments as normal, questionable, or abnormal would improve reliability, validity, 
sensitivity, and specificity of the tool.  Thirty-four preterm infants were administered 
the Premie-Neuro at least once per week in the neonatal intensive care unit (NICU) 
through 37 weeks post-menstrual age (PMA) or discharge, whichever occurred first.  
At 38-42 weeks PMA, infants were assessed using the NeoNeuro, a reliable and valid 
standardized test for term newborns up to 16 weeks adjusted age.  At 3 months 
adjusted age, infants were assessed using the Infanib and Alberta Infant Motor Scale 
(AIMS), two reliable and valid standardized assessments for infants up to 18 months 
adjusted age.  Data were analyzed to determine (1) if mean scores obtained on 
discharge Premie-Neuro assessments were different for infants who later scored in the 
abnormal versus normal ranges on term and 3-month follow-up assessments and (2) if 
changing the raw score cut-point used classify an assessment as abnormal enhanced 
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reliability and validity of Premie-Neuro classifications.  We found that, after 34 
weeks PMA, mean Premie-Neuro scores for infants with abnormal follow-up were 
less than 90.  Infants with discharge Premie-Neuro raw scores less than 90 performed 
significantly worse on term and 3-month follow-up assessments than infants with 
scores 100 or greater.  Using a raw score cut-point of <90, rather than the currently 
recommended cut-point of <100, for classifying an assessment as not normal 
enhanced test-retest reliability, stability, construct validity, and predictive validity of 
the Premie-Neuro classifications.  As expected, using the raw score cut-point of <90 
improved specificity of detecting neurological abnormalities at term and 3 months 
adjusted age, but resulted in much lower sensitivity.  Based on these data, we suggest 
that the clinician may use a Premie-Neuro raw score cut-point of <90 to more reliably 
identify at-risk infants who may benefit from early intervention services and/or close 
follow-up.  However, we caution that using a raw score cut-point of <90 may fail to 
identify a handful of infants who will later demonstrate neurodevelopmental 
abnormalities at term or 3 months adjusted age.  Thus, we suggest that infants with 
Premie-Neuro raw scores of 90-99 be classified as questionable, meaning that these 
babies should be re-tested or monitored closely to ensure that neurological 





 The rate of preterm birth has increased steadily in the United States over the 
last several decades.  Currently, over 12% of all births occur prior to 37 weeks 
completed gestation (1).  Recent advances in neonatal care have resulted in improved 
developmental outcomes for preterm babies (6, 7).  However, there continue to be 
large numbers of children with disabilities and delays resulting from prematurity, and 
there are few standardized assessment tools available for the neonatal clinician to 
identify preterm infants at-risk for such disabilities (2-5, 36).  The Premie-Neuro is a 
new standardized clinical neurological assessment tool for preterm infants (14).  It 
consists of 3 subscales, each containing 8 items.  The Neurologic subscale assesses 
primitive reflexes and passive tone, the Movement subscale examines behavioral 
signs of stress, and the Responsiveness subscale assesses active tone and 
responsiveness to handling.  Because items included in the Responsiveness subscale 
require changing the infant’s position—and may therefore be stressful for the very 
young or very sick preterm infant—this subscale may only be administered to infants 
who are older than 28 weeks PMA and who are not ventilator-dependent.  Based on 
the infant’s age and performance, he is given a score on each item.  Item scores are 
tallied for a total raw score, and the raw score is converted to a classification of 
normal, questionable, or abnormal based on raw score cut-points recommended in 
The Premie-Neuro Examination Instruction Manual (78).  The Premie-Neuro is 
unique in that it can be administered in less than 10 minutes without removing the 
infant from his crib or isolette and without interfering with electronic monitoring or 
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mechanical ventilation, and may be given to preterm infants as young as 23 weeks 
PMA (14, 78).  These characteristics make the Premie-Neuro a promising tool for 
serial clinical neurological assessment in the NICU, providing clinicians with a quick, 
objective criterion for identifying at-risk preterm infants who may require extra 
supports and services and/or close developmental follow-up. 
 In Chapters 2 and 3, we reported that Premie-Neuro raw scores had 
acceptable reliability, could differentiate between infants at high- and low-risk for 
poor neurological outcomes, and were predictive of outcomes at term and 3 months 
adjusted age.  However, Premie-Neuro classifications (normal, questionable, and 
abnormal) based on raw score cut-points recommended by the authors of the Premie-
Neuro were not reliable and valid.  In the present study, we retrospectively analyzed 
predictive validity data originally presented in Chapter 3 to determine whether there 
was a significant difference in discharge Premie-Neuro raw scores in infants who 
performed in the abnormal versus normal range at term and/or 3 month follow-up 
testing.  Using that data, we identified a possible new raw score cut-point for 
classifying an abnormal assessment and re-analyzed data originally presented in 
Chapters 2 and 3 to determine if using the new cut-point resulted in improved 






 Thirty-four preterm infants (mean gestational age at birth 29 ±3.7 SD weeks, 
birth weight 1343 ± 696 SD grams) participated in this study.  Infants were included 
in the study if they were born prior to 37 weeks gestation and were no more than 37 
weeks PMA at the time of the first Premie-Neuro assessment.  Infants with a known 
genetic disorder or major congenital anomaly were excluded from the study.  Prior to 
participation in the study, each participant’s parent or guardian signed an 
institutionally approved parental consent form. 
 
Premie-Neuro testing 
Once the infant’s physician determined he or she was medically stable enough 
to participate, Premie-Neuro testing began.   All Premie-Neuro tests were 
administered by a physical therapist.  Testing was conducted in the infant’s crib or 
isolette and was scheduled within one hour prior to the infant’s regular feeding time 
when possible.  Heart rate and oxygen saturation were monitored during each 
assessment, and testing was discontinued and/or canceled and rescheduled if the 
infant showed significant signs of stress during the testing, was acutely ill the day of 
testing, or if the infant or examiner were unavailable during the scheduled testing 
time.   
During the first week of testing, the Premie-Neuro was administered twice, no 
more than 72 hours apart.  Premie-Neuro testing continued approximately weekly 
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(once every 5-9 days) by the same examiner through 37 weeks PMA or discharge, 
whichever occurred first.  
 In accordance with the Premie-Neuro Examination Instruction Manual, each 
Premie-Neuro item was assigned a score of 1, 3, or 5 based on the infant’s gestational 
age and performance on the item. Item scores were tallied for a total raw score (14).   
 
Follow-up testing at term adjusted age  
 At 38-42 weeks PMA, the NeoNeuro was administered.  The NeoNeuro is a 
reliable and valid standardized test that assesses active and passive tone, reflexes, and 
neurobehavior in infants 38 weeks PMA through 16 weeks adjusted age (65, 95).  If 
the infant remained in the NICU at term adjusted age, testing was conducted at 
bedside.  If the infant was discharged from the NICU, testing was conducted in the 
home or the NICU follow-up clinic, depending on parent or caregiver preference.  In 
accordance with administration guidelines, each NeoNeuro item was assigned a score 
of 1, 3, or 5 based upon the infant’s adjusted age and performance on the item.  Item 
scores were tallied for a total raw score, and infants were classified as normal, mildly 
abnormal, moderately abnormal, or severely abnormal based on cut-points 
recommended by the NeoNeuro authors (65, 95).  For this study, NeoNeuro 
assessments classified as normal or mildly abnormal were considered normal at term 
follow-up, and assessments classified as moderately or severely abnormal were 




Follow-up testing at 3 months adjusted age 
 Two reliable and valid standardized assessment tools were used to examine 
study participants at 3 months adjusted age:  the Infanib (90) and the Alberta Infant 
Motor Scale (AIMS) (90, 96).  No infants remained in the NICU at 3 months adjusted 
age, so testing was conducted in the infants’ homes or the NICU follow-up clinic, 
according to parent or caregiver preference.  
The Infanib is a criterion-referenced standardized test that assesses tone, 
reflexes, and posture.  Infants in the present study were tested with the Infanib 
according to administration guidelines and were classified as neurologically normal, 
transient, or abnormal based on total raw score cut-points recommended by the 
Infanib authors (90).  The AIMS is a reliable and valid, norm-referenced test of motor 
development for infants 0-18 months adjusted age (68, 96).  In this study, the AIMS 
was administered in a standardized fashion as described in the administration manual 
(96).  Based on total raw score, each infant was assigned a percentile rank.  Using the 
criteria recommended by Darrah and colleagues, infants with a percentile rank at or 
above the 10th percentile were classified as normal, while infants who scored <10th 
percentile were classified as abnormal (97).  For this study, infants with Infanib 
assessments classified as abnormal OR an AIMS scores <10th percentile were 
considered abnormal at 3-month follow-up.  Infants with Infanib assessments 
classified as transient or normal AND an AIMS score ≥10th percentile were 




Demographic and medical factors 
At the time of enrollment in the study, the infant’s birth weight, sex, and 
gestational age at birth were obtained by reviewing the infant’s medical chart.  At 
discharge, the infant’s medical chart was reviewed to obtain the following 
information:  blood pH history, seizure activity, diagnosed central nervous system 
injury including IVH/PVH and periventricular leukomalacia (PVL), respiratory 
history (including need for mechanical ventilation), and history of hypoglycemia.  
These data were used to calculate a Neurobiologic Risk Score (NBRS) for each infant 
(86).  Based on the criteria described by Brazy and colleagues, infants with a 
discharge NBRS of <5 were considered  “low risk”  (Low Risk Group, LR) and 
infants with a discharge NBRS of ≥5 were considered  “intermediate/high risk” (High 
Risk Group, HR) for neurological injury and poor neurodevelopmental outcomes 
(85).   
 
Data analysis 
 Only scores obtained for the full Premie-Neuro—all three subtests—were 
included in data analyses for this study.  We performed retrospective analyses of 
Premie-Neuro assessment results obtained in the NICU to compare Premie-Neuro raw 
scores for infants with normal follow-up testing at term and 3 months adjusted age 
versus infants with abnormal follow-up testing at term or 3 months adjusted age.  
Based on those data, we chose to analyze test-retest reliability, stability, construct 
validity, and predictive validity of Premie-Neuro classifications using a new raw 
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score cut-point of <90 to classify a Premie-Neuro assessment as 
questionable/abnormal.  We compared this to reliability and validity analyses 
presented in Chapter 2 and 3 (using the author-recommended raw score cut-point of 
100) to determine whether modification of raw-score cut-points improved test-retest 
reliability, stability, validity, sensitivity, and specificity and Premie-Neuro 
classifications.   
 Kappa agreements were used to analyze one-day test-retest reliability of 
Premie-Neuro classifications.  To examine the stability of Premie-Neuro 
classifications, we determined the most frequent classification for each infant, and 
calculated the percentage of assessments that each infant tested in his or her most 
frequent classification.   
In Chapters 2 and 3, we found that the last Premie-Neuro scores obtained prior 
to discharge from the NICU had significantly better construct and predictive validity 
than the first Premie-Neuro scores.  Thus, for this study, we used only discharge 
Premie-Neuro classifications to analyze construct and predictive validity, sensitivity 
and specificity.  If an infant was only tested once in the NICU, that score was 
considered the discharge Premie-Neuro assessment.  Fisher’s exact test was used to 
determine if a larger proportion of low-risk infants tested in the normal classification 
compared to high-risk infants.  To examine predictive validity of Premie-Neuro 
classifications, we collapsed classifications of all follow-up assessments into two 
classifications—normal and not normal.  NeoNeuro assessments in the normal range 
were classified as normal, while assessments in the mildly, moderately, and severely 
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abnormal ranges were classified as not normal.  Similarly Infanib assessments in the 
normal range were classified as normal while assessments in the transient or 
abnormal range were classified as not normal.  Finally, AIMS scores <10th percentile 
were classified as not normal while scores above the 10th percentile were classified as 
normal.  We compared discharge Premie-Neuro classifications to NeoNeuro 
classifications at term and Infanib and AIMS classifications at 3 months adjusted age 
using Fisher’s exact test.  In order to assess the relationship between risk factors (GA 
at birth, CNS injury, and oxygen dependence at 36 weeks) and discharge Premie-
Neuro classifications, logistic regression was used.  Analyses were performed with 




Premie-Neuro scores in infants who were abnormal versus normal at follow-up 
 Table 4.1 provides descriptive information about the infants who participated 
in this study.  One infant could not be tested for term or 3-month follow-up, and was 
therefore not included in either the normal or abnormal follow-up groups.  At early 
gestational ages, there was little difference in Premie-Neuro scores between infants 
who were normal versus abnormal at follow-up.  However, beginning at 
approximately 33-34 weeks PMA, scores for infants who were normal at follow-up 
remained consistent, while scores for infants who were abnormal at follow-up 
worsened (Figure 4.1).  Mean Premie-Neuro scores from 35-37 weeks PMA for the 
xcv                                                 
∗ SPSS, 233 S. Wacker Drive, Chicago, Illinois, 60606 
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normal follow-up group ranged from 96.3-99.3, while raw scores for the abnormal 
follow-up group ranged from 80-87.7 (Table 4.2). Premie-Neuro raw scores for 
individual subjects are plotted in Figure 4.2.a. and 4.2.b. 
 Figure 4.3 shows performance at term (4.3.a) and 3-month (4.3.b and 4.3.c) 
follow-up for infants with discharge Premie-Neuro raw scores <90, 90-99, and >99.  
Analysis of variance revealed that infants with discharge Premie-Neuro raw scores 
<90 performed significantly worse on NeoNeuro assessments at term (p=0.000) and 
Infanib and AIMS assessments (p=0.001 and p=0.009, respectively) at 3 months 
adjusted age compared to infants with discharge Premie-Neuro scores >99.  
Compared to infants with discharge Premie-Neuro scores ranging from 90-99, infants 
with discharge Premie-Neuro scores <90 performed significantly worse on NeoNeuro 
assessments at term (p=0.000) and Infanib assessments at 3 months adjusted age 
(p=0.025) but not on AIMS assessments at 3 months adjusted age.   These data 
indicated that there were significant differences in developmental and neurological 
outcomes at term and 3 months adjusted age in infants with discharge Premie-Neuro 
scores <90 compared to infants with raw scores 90-99 or  above 99.  Thus, we chose 
to conduct reliability and validity analyses of Premie-Neuro classifications using a 
total raw score of ≥90 to classify an assessment as normal. 
 
Reliability 
  Of the original 34 infants, 4 infants were not administered all three subtests of 
the Premie-Neuro during test-retest reliability testing, and 4 infants were discharged 
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from the NICU before the test could be administered on day 2.  Thus, 26 infants were 
included in our analyses of short-term test-retest reliability.  Using a total raw score 
of 90 as a cut-point, test-retest reliability of Premie-Neuro classifications was 
moderate according to criteria described by Landis and Koch (88), and was 
statistically significant (Kappa=0.469, p=0.005).   
 Eight infants were discharged from the NICU before they were given a second 
weekly Premie-Neuro test.  Thus, week-to-week stability of Premie-Neuro 
classifications was analyzed for 26 infants.  Using a total raw score of 90 as a cut-
point, 18 infants tested most frequently in the normal classification, 6 infants tested 
most frequently as questionable, and 2 infants had an equal number of tests in the 
normal and questionable classifications.  The mean percentage of assessments that 
each infant tested in his or her most frequent classification was 84.5 (±18.5%).  Test-
retest reliability and stability data with comparisons to data presented in Chapter 2 
(analyzed using a raw score cut-point of 100) are summarized in Table 4.3. 
 
 Construct validity 
 Ten infants were categorized as high risk (HR) using the NBRS, while 24 
were classified as low risk (LR).  Using a total raw score of 90 as a cut-point, a 
significantly larger proportion of HR infants than LR infants were classified as 
questionable at the discharge Premie-Neuro assessment (p=0.000).  Oxygen-
dependence at 36 weeks was a significant predictor of Premie-Neuro classifications 
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(p=0.034), but gestational age at birth and presence of CNS injury were not 
significant predictors (Table 4.4). 
 
Predictive validity 
 One infant’s family could not be contacted for term follow-up.  Thus, 33 
infants were included in analyses for predictive validity of discharge Premie-Neuro 
classifications at term adjusted age.  Using a total raw score cut-point of <90 to 
classify an assessment as not normal, the discharge Premie-Neuro classifications were 
significantly associated with NeoNeuro classifications at term (p=0.045) and 
discharge Premie-Neuro classifications were 44.4% sensitive and 92.3 % specific in 
detecting a not normal NeoNeuro classification at term. 
 At 3 months adjusted age, five infants’ families could not be contacted, three 
infants’ families had relocated, and one infant was deceased.  The 25 remaining 
infants were included in analyses for predictive validity of discharge Premie-Neuro 
classifications at 3 months adjusted age.  Using a total raw score of 90 as a cut-point, 
discharge Premie-Neuro classifications were significantly association with AIMS 
(p=0.035) but not Infanib (p=0.130) classifications at 3 months adjusted age.  
Discharge Premie-Neuro classifications were 35.3% sensitive and 100% specific in 
detecting a not normal classifications on the Infanib and 75% sensitive and 85% 
specific in detecting abnormal classifications on the AIMS at 3 months adjusted age.  
Table 4.5 describes predictive validity data using a raw score cut-point of <90 to 
classify an assessment as not normal compared to data presented in Chapter 3, where 
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 Although there is no question that preterm infants are at greater risk for 
developmental delay and disability than their term peers, the majority of preterm 
babies grow up with no significant developmental disabilities or delays.  A 
disproportionate amount of early intervention dollars are spent to provide services 
such as physical and occupational therapy to preterm infants (64), but research shows 
that these services do not result in improved motor outcomes when they are provided 
to preterm infants simply because they are preterm (8-11).  However, when provided 
to preterm babies who have been identified as high-risk using a standardized 
assessment tool, studies have shown that these services do have a positive effect on 
motor outcomes (12, 13).  In order to ensure that early intervention services are 
provided to preterm children in an appropriate, effective, and cost-efficient manner, it 
is critically important that neonatal care providers have access to standardized tools to 
objectively identify babies most at-risk for developmental disability and delay and 
who will, therefore, benefit from early intervention services. 
The Premie-Neuro holds promise as a tool that may be used by the clinician 
for repeated standardized clinical neurological assessments in the NICU.  It is brief 
(takes less than 10 minutes to administer), non-invasive and non-stressful for the 
infant, and requires minimal training for an experienced clinician. Our previous work 
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shows Premie-Neuro raw scores are reliable and valid for identifying at-risk infants in 
the NICU.  However, currently recommended Premie-Neuro raw score cut-points for 
classifying infants as normal, questionable, or abnormal are not reliable and valid and 
must be interpreted cautiously by the clinician.  Although the reliability and validity 
of raw scores make the Premie-Neuro a valuable tool, it is important that the clinician 
have some sort of criteria to use to interpret scores, so that they can determine which 
babies are most at-risk for delays and/or disabilities.  A reliable and valid method for 
classifying Premie-Neuro assessments as normal or not normal—and thus identifying 
preterm babies as low- or high-risk—would greatly enhance the clinical utility of the 
tool. 
In the present study, our data indicated that prediction of term and 3-month 
outcomes may not be possible until 33-34 weeks PMA using the Premie-Neuro.  
Before that time, babies in our study who would later show neurological 
abnormalities often tested in the normal range, with declining scores only as they 
approached term adjusted age.  This is consistent with our previous work, presented 
in Chapters 2 and 3, that showed that discharge Premie-Neuro assessments were more 
reliable and valid than earlier assessments.  This does not necessarily mean that 
earlier Premie-Neuro assessments are not valuable—babies with low early Premie-
Neuro scores should certainly be monitored closely and/or provided with services to 
address deficits—but that an early normal test probably does not effectively rule out 
neurodevelopmental delay or disability.  It is important to note that, in our sample, 
mean total scores for babies with abnormal follow-up dropped below 90 after 34 
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weeks PMA and remained <90 through term adjusted age.  Thus, a raw score of <90, 
particularly at 35-37 weeks PMA, may be indicative of persistent neurological 
abnormality.  Repeated testing through at least 34 weeks PMA is recommended to  
help ensure that babies with developing abnormal neurological signs are identified, 
and continued testing through the first months of life using the Premie-Neuro and 
other standardized tools may determine whether such abnormalities are transient or 
persistent. 
Our study also showed that infants with discharge Premie-Neuro raw scores 
<90 performed significantly worse on assessments administered at term and 3 months 
adjusted age than babies with higher scores, particularly compared to babies with 
scores ≥ 100.  Using a total raw-score cut-point of <90, rather than using the currently 
recommended cut-point of <100, to classify an assessment as not normal resulted in 
better reliability, validity, and specificity of discharge Premie-Neuro classifications.  
While further testing with larger samples are needed, at this time it seems most 
appropriate to suggest that the clinician refer a preterm infant for early intervention 
services and/or careful follow-up if his or her Premie-Neuro score is <90 at 35-37 
weeks PMA.  However, if is important to note that—although specificity of discharge 
Premie-Neuro classifications was better using the raw score cut-point of <90, 
sensitivity was worse.  For the clinician, this means that using the modified raw-score 
cut-point of <90 will result in fewer false-positive assessment results, effectively 
doing a better job at identifying babies who are truly at-risk, but will result more 
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false-negatives assessments, meaning that a handful of at-risk babies will be missed 
using the new cut-point.   
While our data showed strong prediction for abnormal term or 3-month 
outcomes in babies with discharge Premie-Neuro scores <90 and normal term and 3-
month outcomes in babies with discharge Premie-Neuro scores ≥100, outcomes for 
babies with discharge Premie-Neuro scores in the 90-99 range were less clear.  The 
majority of babies with discharge Premie-Neuro scores in the 90-99 range will 
probably develop normally, but there are a handful of those babies for whom 
neurological delays and/or disabilities may emerge over time.   Based on our data, 
babies with scores in this range should be classified as questionable or suspect and 
should be re-tested and/or followed carefully to determine whether their borderline 
scores are indicative of true neurological disability or are simply evidence of mild 
delays and/or transient, resolving neurological signs.  Premie-Neuro assessment 
results for these babies may be combined with other data—such as results of 
neuroimaging—and clinical judgment for making decisions on whether to refer these 
babies for early intervention services.     
A limitation of this study is the relatively low sample size.  We tested 34 
infants in this study and, due to circumstances such as early NICU discharge or 
inability to contact families at follow-up, some analyses included as few as 26 
subjects.  Perhaps because of this, there was little variation in Premie-Neuro raw 
score between infants, and no infant scored in the abnormal range (raw score <70 as 
recommended by the Premie-Neuro authors) during the course of the study.  
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Currently, the Premie-Neuro recommends 3 classifications based on raw-score cut-
points (normal: ≥100; questionable: 70-99; abnormal: <70).  Because the infants in 
our study only tested in two classifications—questionable and normal—we collapsed 
all assessments into 2 classifications (normal and not normal) for our analyses.  
Future studies with larger groups of infants may result in greater variation in 
performance, allowing further analyses of Premie-Neuro classifications to be done 
using a 3-classification system rather than 2. 
Another limitation of this study is that the participants were only followed 
through 3 months adjusted age.  Over 25% of the infants in our study had abnormal 
assessment results at term and/or 3 months adjusted age.  Research shows that major 
disability, such as cerebral palsy, generally occurs in 7-20% of preterm infants, with 
the average generally falling around 10-15% (3, 32, 41-44).  Thus, it is unlikely that 
all 9 of the infants in our abnormal follow-up group will truly have significant 
neurodevelopmental abnormalities.  Follow-up testing of the infants in this study will 
continue through at least 2 years of age to determine if abnormalities tend to resolve 
in some babies and, if so, if the Premie-Neuro was able to predict which babies would 




 The results of this study show that, after approximately 34 weeks PMA, the 
Premie-Neuro does differentiate between infants with normal versus abnormal 
performance on standardized assessments administered at term and 3 months adjusted 
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age.  Infants with discharge Premie-Neuro scores <90 performed worse on all 
assessments administered at term and 3 months adjusted age than infants with scores 
≥ 100, but there were not clear differences among infants with scores in the 90-99 
range, particularly at 3 months adjusted age.  Using the Premie-Neuro raw score cut-
point of <90 to classify an assessment as not normal resulted in better reliability, 
validity, and specificity versus using the currently recommended cut-point of ≥100.  
Based on these data, we recommend that infants with Premie-Neuro raw scores <90 at 
35-37 weeks PMA be classified as not normal or at-risk and be referred for more in-
depth, specialized testing and/or early intervention services.  Babies with raw scores 
in the 90-99 range should be classified as questionable, and babies with raw scores 
≥100 be classified as normal.  As the Premie-Neuro becomes more widely used, 
future research will be needed to determine if these cut-points are indeed appropriate 
for identifying at-risk infants and to examine whether the Premie-Neuro may be 




Table 4.1. Description of study participants.  Data are mean (standard 
deviation).  One infant could not be contacted for term or 3-month follow-up 
testing, and was therefore not included in either the normal or abnormal follow-
up group.  GA=Gestation Age; BW=Birth Weight. 





Birth order Race/ 
ethnicity  
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Table 4.2. Premie-Neuro raw scores for infants with abnormal follow-up 
assessments (abnormal NeoNeuro at term or abnormal Infanib or AIMS at 3 
months AA), normal follow-up assessments (normal NeoNeuro at term and 
normal Infanib and AIMS at 3 months adjusted age), and all participants at 
each week PMA.  Data are mean (standard deviation).  Data from infants 
assessed at PMA weeks 29 and 30 were omitted as there was only one data point 
at 29 weeks and no data points for 30 weeks in the abnormal follow-up group. 




 Total Raw Score Cut-
point 
 90 100* 
One-day test-retest reliability (n=26) 
 
κ=0.469 κ=0.137 
Stability (% weekly assessments in most frequent 
classification, n=26) 
84.5% 79.5% 
Table 4.3. Reliability and stability of Premie-Neuro classifications using raw 
score cut-points of 90 and 100.  Raw scores at or above the cut-point were 
classified as normal, while raw scores below the cut-point were classified as not 
normal.  Using the raw score cut-point of 90 resulted in improved test-retest 
reliability and stability of the Premie-Neuro. 




 Total Raw Score Cut-point 
 90  100* 
Proportion of HR vs. LR 
infants classified as 
“questionable”  
(Fisher’s exact test) 
 
p=0.000**  p=0.191 
Significant predictors of 
Premie-Neuro classifications  
(Logistic regression with CNS 
abnormalities, GA at birth, and  
oxygen-dependence at 36 weeks 
entered as independent 
variables) 
Oxygen-dependence at 
36 weeks (p=0.034**) 
 Oxygen-dependence at 
36 weeks (p=0.048**) 
Table 4.4. Construct validity of Premie-Neuro classifications using raw score 
cut-points of 90 and 100.  Raw scores at or above the cut-point were classified as 
normal, while raw scores below the cut-point were classified as not normal.  
There was a significantly larger proportion of high-risk infants classified as not 
normal using a cut-point, but no group differences using a cut-point of 100.  
Oxygen-dependence at 36 weeks, but not CNS abnormality, was predictive of 
Premie-Neuro classifications using both cut-points.  GA at birth was not 
included in either regression model due to lack of significance.  HR=High Risk 
Group; LR=Low Risk Group; CNS=Central Nervous System; GA=Gestational 
Age.   





 Total Raw Score 
Cut-point 
 90 100* 
NeoNeuro (term) 
Proportion of infants classified as  
not normal on PN who were also classified  
as not normal on the NN  
























Infanib (3 months adjusted age) 
Proportion of infants classified as  
not normal on PN who were also classified  
as not normal on the INF  
























Alberta Infant Motor Scale  
(3 months adjusted age) 
Proportion of infants classified as  
not normal on PN who were also classified  
as not normal on the AIMS  

























Table 4.5. Predictive validity of the Premie-Neuro using raw score cut-points of 
90 and 100.  Raw scores at or above the cut-point were classified as normal, 
while raw scores below the cut-point were classified as not normal.  Using a raw 
score cut-point of 90 improved predictive validity and specificity of the Premie-
Neuro at term and 3 months adjusted age, but resulted in worse sensitivity.  
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PN=Premie-Neuro; NN=NeoNeuro; INF=Infanib; AIMS=Alberta Infant Motor 
Scale. 
*Data from Chapter 3, **p<0.05 
 
 111
4.7 Figure Legend 
 
Figure 4.1. Mean Premie-Neuro total raw scores from 29-37 weeks post-menstrual 
age (PMA) in infants with normal term and 3-month follow-up assessments versus 
infants with abnormal results on assessments administered at term or 3 months 
adjusted age.  After approximately 34 weeks PMA, Premie-Neuro scores for infants 
with normal follow-up remained stable, while scores for infants with abnormal 
follow-up worsened. 
 
Figure 4.2. Premie-Neuro total raw scores from 29-37 weeks post-menstrual age 
(PMA) for individual subjects with (a) normal term and 3-month follow-up 
assessments and (b) abnormal results on assessments administered at term or 3 month 
adjusted age.   
 
Figure 4.3. Mean performance on (a) the NeoNeuro at term and (b) the Infanib and 
(c) the Alberta Infant Motor Scale (AIMS) at 3 months adjusted age for infants with 
discharge Premie-Neuro scores <90, 90-99, and >99. Infants with discharge Premie-
Neuro raw scores <90 performed significantly worse than infants with discharge 
Premie-Neuro scores >99 on all term and 3-month follow-up tests, and performed 
significantly worse than infants with discharge Premie-Neuro scores 90-99 on the 
NeoNeuro at term and the Infanib at 3 months adjusted age.  There was no difference 
between infants with discharge Premie-Neuro scores 90-99 and infants with discharge 









































Summary and Conclusions 
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5.1 Summary of findings 
 
The primary purpose of the work presented in this dissertation was to 
determine the reliability and validity of the Premie-Neuro, a relatively new clinical 
test of neurological development for the preterm infant age 23-37 weeks post-
menstrual age (PMA).  A secondary goal was to determine what modifications of the 
test, if any, may be recommended to potentially improve the reliability and validity of 
the tool.  Prior to the present study, internal consistency of the Premie-Neuro had 
been established (14) and pilot work had shown that the Premie-Neuro may be 
predictive of outcomes through 6-8 months adjusted age (79), but no other study had 
shown whether the Premie-Neuro had acceptable reliability and validity for clinical 
use.  Overall, the body of work presented in this dissertation showed that Premie-
Neuro raw scores had acceptable interrater and test retest reliability (Chapter 2), good 
construct validity (Chapter 2), and the ability to predict outcomes at term and 3 
months adjusted age (Chapter 3).  Although Premie-Neuro classifications (normal, 
abnormal, and questionable) based on currently recommended raw score cut-points 
were not as reliable and valid as raw scores, we used our data to recommend 
modifications to Premie-Neuro classifications that seemed to improve their reliability 
and validity (Chapter 4).  These results may allow for earlier identification of 
neurodevelopmental disabilities in preterm infants in the neonatal intensive care unit 
(NICU), and better decision-making for referrals for specialized early intervention 




Chapter 2.  The Premie-Neuro: A reliable and valid clinical neurological test for 
preterm infants in the NICU. 
 The purpose of Chapter 2 was to determine if Premie-Neuro raw scores and 
classifications (normal, abnormal, or questionable) based on raw score cut-points 
recommended by the assessment’s authors had acceptable reliability and validity for 
clinical use.  We found that interrater and test-retest reliability of raw scores—
although lower than reliability previously reported for other assessments designed for 
older preterm and term newborns (65, 68, 72, 90, 92, 95, 96)—was fair to moderate, 
representing clinically significant reliability of the Premie-Neuro for this population.  
Construct validity of the Premie-Neuro raw scores was strong as the assessment was 
able to differentiate between infants at different risk for poor outcomes.    Although 
stability of Premie-Neuro classifications was good from week to week, interrater and 
test-retest reliabilities and construct validity of Premie-Neuro classifications were 
inadequate.  Thus, our work in Chapter 2 suggested that, as the Premie-Neuro is 
currently structured, raw scores may be used to reliably identify at-risk babies in the 
NICU, but classifications must be interpreted carefully. 
 
Chapter 3.  Predictive Validity of the Premie-Neuro at Term and 3 Months Adjusted 
Age. 
 One of the biggest challenges in neonatal neurological assessment is 
determining which babies are demonstrating true, persistent neurological 
abnormalities and which babies’ abnormal neurological signs will resolve over time.  
 
 121
Thus, predictive validity—the ability for performance on an assessment to predict 
future performance on a different assessment—is of considerable importance to the 
clinician.  The goal of Chapter 3 was to determine whether Premie-Neuro 
performance in the NICU could predict performance on the NeoNeuro at term 
adjusted age and the Infanib and Alberta Infant Motor Scale (AIMS) at 3 months 
adjusted age.  We found that Premie-Neuro classifications and early Premie-Neuro 
raw scores generally had poor predictive value.  However, Premie-Neuro raw scores 
obtained shortly before discharge from the NICU (generally after 34-35 weeks PMA) 
were significantly associated with outcomes at term and 3-months adjusted age.  This 
provided strong evidence that, as infants approach term adjusted age, the Premie-
Neuro raw scores were able to identify neurological abnormalities that would persist 
through at least 3 months adjusted age.  Thus, discharge Premie-Neuro raw scores 
may be used to make recommendations for follow-up and/or necessity of early 
intervention services. 
 
Chapter 4.  Modifying raw score cut-points improves reliability, validity, and 
predictive value of Premie-Neuro classifications. 
 Despite the fact that the Premie-Neuro raw scores had acceptable reliability 
and strong construct and predictive validity, reliability and validity of the Premie-
Neuro classifications were generally weak (Chapter 2, Chapter 3).  Thus, in Chapter 
4, we retrospectively analyzed the data presented in Chapters 2 and 3 to determine if 
the raw score cut-points used for classifying a Premie-Neuro assessment as normal, 
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questionable, or abnormal could be modified to improve reliability and validity, 
thereby enhancing the clinical usefulness of the tool.  We found that infants with 
Premie-Neuro raw scores <90 after approximately 34 weeks adjusted age performed 
significantly worse on all assessments at term and 3 months adjusted age than infants 
with Premie-Neuro raw scores ≥100 and significantly worse on the NeoNeuro at term 
and the Infanib at 3 months adjusted age than infants with scores in the 90-99 range.  
Thus, we re-analyzed all data using a raw score cut-point of <90 to classify an 
assessment as not normal and found improved reliability, validity, and specificity 
using the new cut-point.  Based on our data, we recommended that the clinician may 
consider an infant not normal or at-risk if he or she scores <90 on Premie-Neuro 
assessments after 34 weeks PMA, and that the infant should be classified as 
questionable and re-tested or closely monitored if he or she scores 90-99.  Infants 
with raw scores >100 may be classified as normal.  However, we caution that more 
research needs to be done to evaluate the reliability and validity of the Premie-Neuro 
using the new cut-points.  Further, the clinician should note that sensitivity of Premie-
Neuro classifications was worse using the raw score cut-point of <90 to classify an 
assessment as abnormal.  Thus, interpreting Premie-Neuro assessments using the raw 
score cut-point of <90 increases the risk of missing an infant who will later 
demonstrate neurological abnormalities. 
 
 123
5.2 Clinical implications 
 
The preterm birth rate has risen 20% since 1990.  In 2006, over 540,000 
infants were born preterm in the United States (1).  Many preterm infants go on to 
develop normally.  However, several recent reviews report that up to 25% of preterm 
infants are eventually diagnosed with major disabilities such as cerebral palsy, and 
the majority of preterm infants may exhibit milder dysfunction in areas such as motor 
coordination, behavior, reading and verbal skills, and cognition (3, 21, 44).  In the 
past, neonatal and pediatric care providers have had very few tools at their disposal 
for early identification of high-risk infants, and it has been long thought that 
neurological disability cannot be diagnosed until at least 1-2 years of age.  However, 
there is mounting evidence that standardized testing in the NICU can predict 
neurodevelopmental outcomes in preterm babies (57, 58).  In this body of work, we 
have shown that the Premie-Neuro is a reliable and valid clinical neurological test and 
that it is predictive of outcomes through 3 months adjusted age.  Because it can be 
administered to infants as young as 23 weeks post-menstrual age in less than 10 
minutes without removing the infant from his or her bed and without interfering with 
mechanical ventilation or electronic monitoring, it is ideal for repeated use during an 
infant’s NICU stay to track his or her neurological development and discriminate 
between transient or persistent neurological signs.  The results of our work have 
implications for the way preterm infants are assessed and cared for in the NICU and 




How early can we identify developmental disability and delay in the preterm infant? 
 In the present study, we found that the Premie-Neuro did not discriminate 
between high- and low-risk infants (Chapter 2), nor did it discriminate between 
infants who would later have normal versus abnormal follow-up outcomes (Chapter 
4), until approximately 34-35 weeks post-menstrual age.  Before that time, mean raw 
scores for all groups of infants tended to be in the normal or near-normal range.  At 
33-34 weeks PMA, mean raw scores for low-risk infants and those with normal 
follow-up at term and 3 months adjusted age remained steady at approximately 95-
100, while means scores for high-risk infants and those with abnormal follow-up at 
term or 3 months adjusted age fell to approximately 80-85 as they approached 37 
weeks PMA.  We do not believe that this means that early Premie-Neuro testing is not 
valuable or should not be done.  However, it does mean that the Premie-Neuro may 
not be sensitive enough to detect abnormalities in some very young preterm infants, 
and an early normal result should not be used to rule out neurological abnormality.  
Repeated testing should be done through at least 34 weeks PMA to ensure that 
abnormal neurological signs do not emerge.  However, an early abnormal result 
should not be ignored and may indicate that further, more in-depth testing or closer 
follow-up may be indicated.   
 
Striking a balance between sensitivity and specificity 
Preterm infants are a highly variable population, both within and between 
babies.  When an infant demonstrates a neurological abnormality, it is difficult to 
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know if that abnormality will persist and lead to significant neurological dysfunction 
or if it is a transient neurological sign that will resolve (2, 3, 21).  Neonatal 
neurological assessment tools are often not sensitive enough to distinguish between 
persistent and transient neurological signs, and although these assessments generally 
have good negative predictive value (children who test in the normal range do well), 
they are notorious for producing high numbers of “false positives ” (65).  That is, 
infants are often identified as having a neurological abnormality when they will in 
fact go on to be neurologically normal.  In this study, there was a tendency to over-
identify assessments as abnormal using the author’s recommended raw score cut-
point of 100.  However, when we lowered the raw score cut-point to 90, we found the 
reverse was true.  There was better specificity and therefore fewer false-positives, but 
worse sensitivity and more false-negatives (the test tended to miss infants who would 
later score in the not normal range on testing at term and 3 months adjusted ages).   
When attempting to identify infants with neurological abnormalities, there 
may be benefits associated with a test with good negative predictive value and a 
tendency toward false positives.  It allows reassurance when an infant is tested as 
neurologically normal, and causes examiners to exercise caution and closely monitor 
“borderline” children whose abnormalities may resolve.  One may argue that it is 
better to provide unnecessary early services  than to deny services to a child who 
needs them, and that is often the position of NICU clinicians and early 
interventionists.  However, research does not provide strong support for specialized 
early intervention services for broad groups of preterm infants (10, 99), and false-
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positives can place undue emotional stress on an infants’ family.  In a time where 
state and federal dollars are scarce, clinicians may need to shift their thinking away 
from providing early intervention services to preterm infants “just in case” and 
toward efficiency and proven effectiveness by using more specific standardized 
assessment tools to better identify high-risk infants who will truly benefit from 
services.  Using a Premie-Neuro raw score of <90 to classify an infant as high-risk at 
or near NICU discharge, as proposed in Chapter 4, resulted in higher specificity and 
fewer false-positive results, making the tool unique compared to other neonatal 
neurological assessments that tend toward higher sensitivity.  We believe that the 
Premie-Neuro and this more conservative approach to interpreting raw scores should 
be used to make better clinical decisions about services for preterm babies.  By 
designating infants with scores of 90-100 as a neurologically questionable group that 
should be re-tested and closely monitored, we hope to minimize the number of false 
negative tests by capturing babies with borderline neurological function and whose 
neurological abnormalities may emerge over time. 
 
Differentiating between transient and persistent neurological abnormalities 
 As mentioned previously, serial neurological assessment of preterm infants is 
critical for distinguishing between persistent and transient abnormalities.  However, 
many currently available assessments are not feasible for repeated clinical use due to 
time constraints and limitations in the ages at which the tests may be used.   Because 
the Premie-Neuro may be administered in less than 10 minutes to all infants in the 
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NICU (from the limits of viability to term adjusted age), it is ideal for providing 
repeated assessments throughout an infant’s NICU stay.  This allows the neonatal 
clinician the unique opportunity to track neurological development and differentiate 
between persistent and resolving neurological abnormalities. 
 
Using Premie-Neuro test results to make decisions about supports, services, and 
follow-up 
 Standardized neurological assessments for preterm and newborn infants 
traditionally classifications of normal, abnormal, and a third category—usually called 
transient or questionable—for infants who score somewhere in between.  While it is 
important to recognize that there are significant numbers of infants with neurological 
signs that are not necessarily “abnormal,” it is sometimes difficult for the clinician to 
interpret these assessments for clinical decision-making, particularly when infants test 
in the “questionable” or “transient” classification.  From a clinical perspective we felt 
that it was important to determine what Premie-Neuro classifications meant in terms 
of long-term outcomes.  We found that, after approximately 34 weeks PMA, infants 
with discharge Premie-Neuro raw scores <90 had significantly worse outcomes at 
term and 3 months adjusted age than scores ≥100.  However outcomes for infants 
with scores 90-99 were less clear.  Using these data, we proposed keeping the 
traditional 3-classification system, classifying scores <90 as abnormal and scores 
≥100 normal, but we recommended narrowing the “questionable” range to include 
scores from 90-99.  For the clinician, that means that infants who score repeatedly 
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<90 should be considered “high-risk” and referred for specialized early intervention 
services or for further, more in-depth testing.  Infants with scores >99 after 34-35 
weeks PMA may be “low risk” with no need for extra services and supports, but 
should still be provided routine follow-up care to make sure that no neurological 
abnormalities emerge.  Our longitudinal data showed that, with multiple assessments, 
many infants with early Premie-Neuro raw scores 90-99 had a tendency to remain 
steady or rise as they approached term if they later had normal outcomes, but tended 
to drop below 90 if their outcomes at term and/or 3 months adjusted age were 
abnormal.   Thus, we recommend that infants with discharge Premie-Neuro scores 90-
99 should be monitored closely to determine neurodevelopmental progress.  In all 
instances, but particularly for infants who test repeatedly in the 90-99 range, it is 
important to combine results of standardized assessments with clinical and medical 
data to make decisions about services and follow-up. 
 
Using the Premie-Neuro to evaluate the effectiveness of neonatal care and 
interventions 
 In addition to allowing the clinician to make better decisions about 
recommending special supports and services for preterm infants, we believe the 
Premie-Neuro may be used to evaluate the effectiveness of those interventions.  
Although clinicians are able to use imaging techniques such as cranial ultrasound or 
MRI to monitor the structure of the preterm infant brain, the Premie-Neuro provides a 
unique opportunity to measure the function of the preterm infant brain over time.  
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This has important implications for both clinical practice and research.  Because it is 
a reliable and valid measure, the Premie-Neuro may be used to quantify brain 
function prior to initiating common NICU intervention such as music therapy, 
kangaroo care, infant massage, or a positioning program.  Repeated Premie-Neuro 
assessments during the course of these interventions or after the intervention period 
has concluded would provide information on the developing brain’s response to these 
interventions, giving some insight as to their effectiveness.  Furthermore, the Premie-
Neuro could be used to assess the effect of developmental care—promoting 
physiological flexion and controlling NICU sounds, light, and temperature to make 
the environment more womb-like—on the preterm infant’s developing brain.  For the 
clinician, the Premie-Neuro would provide a baseline against which to measure an 
individual infant’s change in brain function over time in response to an intervention.  
For the researcher, the Premie-Neuro could be used in randomized controlled trials to 
determine the effect of NICU interventions on groups of infants.   
 
5.3 Limitations 
Setting of the study 
 All Premie-Neuro testing was conducted in the NICU at bedside rather than in 
a standardized lab, clinic, or exam room.  Because the infant was not removed from 
his or her crib or isolette or the NICU, testing time was often flexible and the infant 
was disturbed very little by the testing.  However, this did not allow for control of 
environmental factors such as sound, light, and temperature; caregiver presence; 
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wires and tubes (electronic monitoring, oxygen, and/or ventilation) in the testing area; 
or height, incline, or type of testing surface.  Follow-up testing was conducted in the 
NICU, NICU follow-up clinic, or infant home, depending on caregiver preferences.  
Again, this did allow for flexibility of testing time but did not allow for control of the 
testing environment.  Testing the infants in a controlled environment may have 
strengthened reliability and, to a lesser extent, validity data.  However, we believe 
that our study provided us with the unique opportunity to observe and test infants in 
their natural environments, and that these data represents reliability and validity that 
would be obtained during testing in a “real-life” situation. 
 Because of the fragile nature of the infants in the NICU environment and their 
unique medical needs, it was not possible to control for medications or 
medical/developmental care provided to the participants in this study.  Further, 
because the infants’ mothers were not part of the study, access to prenatal history data 
was limited.  Thus, we were unable to control for factors that may have influenced 
prenatal development such as poor prenatal nutrition or prenatal drug exposure. 
  
Subjects and subject characteristics 
Thirty-four infants participated in this study, 4 more than we initially 
proposed.  This was a sample of convenience recruited from the NICU at Overland 
Park Regional Medical Center.  Unfortunately, our sample was relatively 
homogenous and consisted primarily of white (79.4%) and male (73.5%) babies.  
Although the racial/ethnic background of the subjects recruited for our study is 
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probably reflective of the community in which the subjects were recruited (Johnson 
County, Kansas), we are unsure why our sample was so heavily male.  There is 
conflicting evidence of whether race or sex play a significant role in 
neurodevelopment (24, 37, 59, 62, 74), and future studies are needed to determine if 
there is a race or gender bias associated with the Premie-Neuro.   
 Although 16 of the 34 participants in this study were born prior to 28 weeks 
completed gestation, no testing on any infant was conducted until at least 29 weeks 
PMA.  This was largely due to health concerns and the difficulty obtaining parental 
consent for testing very young, medically fragile infants.  Although the Premie-Neuro 
is designed for infants as young as 23 weeks PMA, the results of this study cannot be 
generalized to infants less than 29 weeks PMA.  However, the difficulty testing very 
young preterm infants in this study is probably reflective of the difficulty testing very 
young, medically fragile infants in any clinical setting.     
We anticipated an attrition rate of up to 10% during the course of this study 
(100).  However, NICU discharge during Premie-Neuro testing resulted in many 
analyses including as few as 22 subjects.  Only one infant (2.9%) was lost to follow-
up at term adjusted age, but 9 (26.5%) were lost at 3 months adjusted age.  Although 
the attrition rate was higher than we anticipated, this was mediated somewhat by our 
larger-than-proposed sample size, and we believe that our sample size provided 
adequate power for the analyses conducted in the present study.  Again, this loss of 
babies to follow-up may be reflective of the challenges faced by neonatal clinicians in 




Examiner training and instruction 
 According to The Premie-Neuro Examination Instruction Manual, “The 
evaluator should study the items in the protocol and the scoring sheet prior to 
administering the evaluation.  It should be practiced repeatedly until the examiner 
feels comfortable with the assessment.  For data collection, it is recommended that 
training on the examination occur and the examiners obtain an interrater reliability of 
0.90 for scoring of the items before data collection occurs.  A video CD or DVD of 
the Premie-Neuro examination is available for viewing (78).”  In the present study, 
the examiner and the observer studied the items and the scoring sheet and practiced 
the examination independently prior to beginning the study.  However, training to the 
0.90 interrater reliability criteria was not done so that we could estimate the true, 
clinical interrater reliability of the Premie-Neuro.  On our sample of 15 infants who 
were tested for interrater reliability, the intraclass correlation coefficients for 
interrater reliability were 0.556 for the Neurologic and Movement subtests and 0.391 
for all 3 subtests (Chapter 2).  Item agreement (percentage of items for which the 
examiner and observer assigned the infant the same score) was 72.1% (Unpublished 
data from Premie-Neuro study).  Although these reliability estimates are clinically 
acceptable for this fragile population, our data indicate that it may take more than 15 
assessments to train to 0.90 interrater reliability or that this level of interrater 
reliability may be difficult to achieve with this assessment in this population.        
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In addition to the inherent lack of neurodevelopmental stability in this 
population, another reason for lower interrater reliability than estimated may be due 
to the item descriptions included in The Premie-Neuro Examination Instruction 
Manual or the subjective nature of scoring for some of the items.  The examiners in 
this study did not note this as a significant limitation for the Neurologic and 
Movement subtests, as scoring these items is typically quantitative (i.e. measuring a 
joint angle or tracking a number of movements per minute).  However, the examiners 
in this study reported that much of the scoring for items in the Responsiveness subtest 
seems somewhat subjective.  For example, when administering the “Posterior Neck” 
item, the examiner holds the infant in a supported sitting position and lets the head 
fall forward.  If the infant does not lift the head, the examiner must determine of the 
infant (a) made no attempt to raise head or (b) tried but could not raise the head (78).    
There is no description of what constitutes an “attempt” or “try,” and it is possible 
that this could be interpreted differently by different examiners.  In our study, where 
interrater reliability was studies using a hands-on examiner and an observer, it was 
extremely difficult for the observer to differentiate between “no attempt” and a “try” 
when there was no movement to observe.  This lack of clear scoring criteria for items 
in the Responsiveness subtest is reflected in our data, as the interrater reliability for 
two subtests was much higher than for all three subtests (Chapter 2).    More specific 
scoring criteria in the instruction manual and/or the instruction video may improve 
reliability of the tool. 
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Test items  
 In our study, we noted that predictive validity of the Premie-Neuro was much 
better as infants approached term adjusted age than at earlier testing (Chapters 3 and 
4).  This is in agreement with research showing little individual stability in motor 
activity and behavior prior to 34 weeks PMA, but improving stability from 35-44 
weeks PMA (101, 102) and work by Korner and colleagues, who identified 32 weeks 
PMA as a “…turning point at which preterm infants behave more like term infants 
than fetuses (70).”  Based on that work as well as the work presented here, it may be 
argued that infants younger than 32-34 weeks PMA may need to be assessed using a 
different type of test than infants older than 34 weeks PMA.  The Premie-Neuro 
addresses this problem to some degree by adjusting the score on each item based on 
PMA and giving a shorter form of the assessment to infants less than 28 weeks PMA 
or on a ventilator, but there are a handful of items that may not be sensitive enough to 
detect abnormalities until an infant is 32-34 weeks PMA.  In fact, there are several 
items, particularly those in the Responsiveness subtest, tended to have this  effect up 
to 32-34 weeks PMA.  For example, for the “Anterior Neck” item, the infant is held 
in a sitting position and the head is allowed to fall backward.  The examiner waits for 
the infant’s response.  Until the age of 34 weeks PMA, “no attempt to raise head” is a 
normal response.  Thus, an infant struggling with head control may not be identified 
by this item until 34 weeks PMA if they are still unable to attempt to raise the head.   
 Conversely, there are many items included in the Premie-Neuro—primarily 
those that assess active and passive tone—that penalize the infant for performing too 
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well.  For example, if an infant is administered the “Anterior Neck” item described in 
the previous paragraph at 33 weeks PMA, it is considered an abnormal response—
indicative of excessive tone—if  the infant holds the head upright and maintains that 
position.  However, this is considered a normal response for an infant at 36 weeks 
PMA.  Just like a normal 4-year-old child can be more mature than average, a normal 
33-week preterm infant can also be more mature than other same-age infants.  In the 
example given, a very mature preterm infant would be given an abnormal score on 
the “Anterior Neck” item at 33 weeks PMA even if the infant’s performance were 
indicative of a very mature brain functioning at closer to the level of 36 weeks PMA, 
and not abnormally high muscle tone.  This early penalization of infants who would 
later score extremely well on the test may be an additional reason why the Premie-
Neuro validity improved significantly as infants approached term adjusted age.  
 
5.4 Future directions 
In the body of work presented in this dissertation, we established that the basic 
psychometric properties—interrater reliability, test-retest reliability, construct 
validity, and predictive validity—of the Premie-Neuro are acceptable for clinical use.  
However, more work is needed to further determine long-term predictive validity of 
the tool.  There are many unanswered questions about “normal” preterm infant 
development as well as the relationship motor development and preterm infant 
physical growth and physiological stability.  Little work has been done to determine 
the effect of specialized care and NICU interventions on brain development and 
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function.  And there are few data on the utilization of early intervention services by 
NICU graduates, and the effectiveness of such interventions.  The following future 
studies may address these questions.   
 
Compilation of normative data for infants in the NICU 
There is a paucity of normative developmental data on preterm infants, 
particularly those less than 32 weeks PMA.  Because we tested infants as young as 29 
weeks PMA, the data collected in this study may be used to begin compiling 
normative data for very preterm and extremely preterm infants.  Performance on each 
individual test item could be tracked according to PMA, comparing infants with 
abnormal follow-up to infants with normal follow-up.  This would give insight into 
the true range of normal passive and active tone, reflexes, movements, and 
responsiveness in young preterm infants and may allow for more precision in 
determining normal versus abnormal performance on individual Premie-Neuro items.  
Future testing of greater numbers of babies may allow for norm-referencing of the 
Premie-Neuro so that each infant’s score may be assigned a percentile rank to 
compare his or her performance to that of same-age peers.  Data collected on infant 
weight, length, and head circumference may be used to determine the relationship 
between physical growth and neurological development.  Physiological data (heart 
rate and oxygen saturation) collected during Premie-Neuro assessments may be used 
to quantify physiological stress experienced by preterm infants during NICU testing 
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and to determine the normal range of physiological responses to handling and 
developmental testing in young preterm babies.   
 
Responsiveness of the Premie-Neuro to specialized early intervention services 
provided in the NICU 
Because preterm infants in the Overland Park Regional Medical Center NICU 
do not routinely receive early intervention physical therapy while hospitalized, the 
data collected in this study characterizes neurological development in preterm infants 
who are receiving routine hospital care and no additional physical therapy 
interventions.  Thus, the infants tested in this study may represent a control group that 
can be used for comparison in future experiments studying the effects of specialized 
early intervention therapy in preterm infants, as well as the Premie-Neuro’s 
responsiveness to such interventions.   
 
Long-term predictive validity of the Premie-Neuro 
In the present study, infants were followed and tested through 3 months 
adjusted age.  Although this gave us an estimate of the short-term predictive validity 
of the Premie-Neuro, there are still questions as to whether the Premie-Neuro has 
long-term predictive value.  Recent reviews by Allen, Aylward, and Bracewell and 
Marlow summarize the general consensus among neonatal care providers that true 
neurological dysfunction and delay may not be able to be detected in the preterm 
infant until at least 18-24 months of age (2, 3, 21, 43).  This is due to the transient 
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neurological abnormalities often exhibited by preterm children—particularly in the 
first year of life—as well as the presence of developmental delays that often resolve 
in this population by two years of age.  Our hope is that the data in this study will 
help provide some insight into factors that may be predictive of long-term 
neurodevelopmental deficits at young preterm ages, and continued follow-up is 
critical to achieving that goal.  The infants included in this study will be followed 
through at least 2 years chronological age, at which time all of the participants in this 
study will be administered the Bayley Scales of Infant and Toddler Development, 
Third Edition (Bayley-III).  The Bayley-III assesses all facets of child development, 
including motor, cognitive, language, adaptive behavior, and social emotional 
development (103).  Its reliability and validity are well-documented, and it is 
considered a “gold standard” for developmental assessment through 42 months of 
age.  This comprehensive testing will provide insight as to whether the Premie-Neuro 
is predictive of developmental outcomes at 2 years chronological age. 
Although significant neurodevelopmental deficits can generally be detected by 
two years of age, it may take longer for more mild delays and disabilities to become 
apparent.  A 2006 study by Salt and colleagues (39) showed that preterm children 
who were “normal” at 3 years often go on to have significant deficits at school-age, 
strengthening the argument that routine NICU follow-up should continue beyond the 
often standard 2 years of age.  Recent research has shown that, although their 
performance may not be in the abnormal range, preterm children generally have 
below average cognitive, reading, math, and motor skills, performing significantly 
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worse in these areas than their term peers.  This appears to be particularly true for 
extremely preterm infants born before 28 weeks completed gestation (30, 31, 33, 34, 
36, 38, 46-52).  These school-age deficits can have a significant impact on school 
success as well as social emotional and behavioral development.  However, there has 
been little work done researching whether these more mild deficits may be identified 
earlier in life so that they may be prevented or possibly treated.  In order to address 
this, our work may be extended beyond the 2-year follow-up to assess the study 
participants at school age and beyond so that we can determine if the Premie-Neuro—
or other data collected in this study—may provide an early indication of future mild 
neurodevelopmental deficits. 
 
Early intervention services after NICU discharge 
 Studies have shown that general developmental care, such as NIDCAP, has a 
positive effect on neurodevelopmental outcomes (8, 39, 80).  However, more 
specialized early intervention services, such as physical therapy, have only been 
shown to significantly affect motor performance if they are performed on infants who 
are identified as “high risk” using a standardized assessment tool (12, 13).  Thus, it 
seems that early intervention services are beneficial, but for only a subset of preterm 
infants.  There are few data describing factors that influence access to and utilization 
of early intervention services by preterm infants and their families.  In our study, we 
provided a questionnaire to parents or caregivers at the 3 month follow up, detailing 
demographic information, parental concerns about their child’s development, and 
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what sort of early intervention services, if any, the child was receiving.  Although 
these data were not analyzed and presented in this dissertation, they may be studied in 
the future to determine what factors influence utilization of early intervention services 
for preterm children and their families.  Because we are in the unique situation that 
this study was conducted near the Kansas-Missouri state line—two states with vastly 
different criteria for eligibility for their States’ early intervention programs—we may 
also be able to determine if there are any differences in utilization of services and 
outcomes in the two states.  Finally, for the preterm children who are receiving early 
intervention services, we may be able to use the data from the questionnaires and the 
outcome measures used in this study to determine if early intervention services are 
effective and—if so—if there are neonatal factors that predict positive outcomes. 
 
5.5 Conclusions 
 In this study, we provide evidence that the Premie-Neuro is a reliable and 
valid clinical neurological test for preterm infants in the NICU, and that performance 
on the Premie-Neuro in the NICU is predictive of outcomes at term and 3 months 
adjusted age.  Further, we propose modification of raw score cut-points for 
classifying an assessment as normal, abnormal, or questionable that may assist the 
clinician in interpreting Premie-Neuro results and using them to make reliable and 
valid decisions for NICU services, follow-up, and referral for early intervention 
services after NICU discharge.  This is the first study to validate a standardized 
assessment tool on preterm infants as young as 29 weeks PMA, and is unique in that 
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even very medically fragile infants were tested, including those who were ventilator-
dependent and who had significant medical complications such as central nervous 
system injury, retinopathy of prematurity, and necrotizing enterocolitis.  Thus, our 
findings may be generalized to the wide range of preterm infants typically admitted to 
the NICU.  The results of this study expand our understanding of preterm infant 
development and provide insight on how early neurological signs may be used to 
predict future neurodevelopmental disability and delay.  Future work will further 
determine the psychometric soundness of the Premie-Neuro, determine how early true 
developmental disability and delay can be detected, and examine how early 
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